Document:

<PAGE>
                                                                   Exhibit 10.20

                          UNITED STATES DISTRICT COURT
                          SOUTHERN DISTRICT OF FLORIDA

                          CASE NO. 99-6181-CIV-GONZALEZ

SANDS POINT PARTNERS, L.P.,
et al., on behalf of themselves and
all others similarly situated,

         Plaintiffs,
vs.

PEDIATRIX MEDICAL GROUP, INC.,
ROGER J. MEDEL, KARL B. WAGNER,
and LAWRENCE M. MULLEN,

         Defendants.

--------------------------------------/

                     STIPULATION AND AGREEMENT OF SETTLEMENT

         This stipulation and agreement of settlement (the "Stipulation"), dated
as of February 7, 2002, is made and entered into by and among lead plaintiffs,
Florida State Board of Administration, Louisiana State Employees' Retirement
System and New Orleans Employees' Retirement System (collectively referred to
herein as the "Lead Plaintiffs"), by and on behalf of themselves and the other
members of the Class (as hereinafter defined), and defendants, Pediatrix Medical
Group, Inc. ("Pediatrix" or the "Company"), Roger J. Medel, Karl B. Wagner, and
Lawrence M. Mullen (the "Individual Defendants") (the Individual Defendants and
Pediatrix are collectively referred to herein as "Defendants"), by and through
their respective counsel.

         WHEREAS:

         a. Beginning on or about February 16, 1999, a number of class action
complaints were filed in the above Court concerning the publicly traded
securities of Pediatrix (the "Pediatrix Class Actions"). The Pediatrix Class
Actions alleged violations of sections 10(b) and 20(a)

<PAGE>

of the Securities Exchange Act of 1934 (the "Exchange Act"), and Rule lOb-5
promulgated thereunder. By Order of Consolidation dated June 24, 1999, ten
actions were consolidated (hereinafter referred to as the "Action"). By Order
dated July 6, 1999, Florida State Board of Administration, Louisiana State
Employees' Retirement System, New Orleans Employees' Retirement System, and
Jacksonville Police & Fire Pension Fund were designated as Lead Plaintiffs
pursuant to Section 21D(a)(3)(B) of the Exchange Act (as amended)1 and the law
firms of Burt & Pucillo, LLP and Bernstein Litowitz Berger & Grossmann LLP were
appointed Co-Lead Counsel for Plaintiffs and the Class.2

         b. A Consolidated Amended Class Action Complaint was filed in the
Action on or about August 20, 1999. On or about October 7, 1999, Defendants
moved to dismiss the Consolidated Amended Class Action Complaint. On January 19,
2000, Defendants' motion to dismiss was granted with leave for Lead Plaintiffs
to replead.

         c. The Second Amended Consolidated Class Action Complaint (the
"Complaint"), filed in the Action on or about February 3, 2000, generally
alleges, among other things, that during the Class Period (hereinafter defined)
Pediatrix engaged in unlawful billing practices, which practices caused
Pediatrix's reported revenues, earnings and accounts receivable for that period
to be overstated thereby artificially inflating the price of Pediatrix common
stock, and that those practices were contrary to the Company's affirmative
public statements regarding its billing practices.

-------------------

1 On or about October 16, 2001, with the agreement of Defendants, Jacksonville
Police & Fire Pension Fund moved to withdraw as a Lead Plaintiff in the Action,
which motion was granted on or about October 29, 2001.

2 Effective July 1, 2001, the firms of Berman DeValerio & Pease, LLP, Berman
DeValerio Pease & Tabacco, P.C., and Burt & Pucillo, LLP merged their practices.
The combined firm is now known as Berman DeValerio Pease Tabacco Burt & Pucillo.

                                       2
<PAGE>

         d. The Complaint further alleges that Lead Plaintiffs and the other
Class members purchased the common stock or call options and sold put options on
Pediatrix's common stock during the Class Period at artificially inflated prices
and were damaged as a result of Defendants' dissemination of false and
misleading statements regarding Pediatrix in violation of sections 10(b) and
20(a) of the Exchange Act and Rule l0b-5 promulgated thereunder.

         e. On or about June 6, 2000, the Court denied Defendants' motion to
dismiss the Complaint. On or about June 26, 2000, the Defendants' Answer was
filed denying the substantive allegations of wrongdoing in the Complaint.

         f. The parties thereafter commenced fact discovery. Throughout the
second half of the year 2000 and most of 2001, the parties engaged in extensive
discovery. Over 200,000 pages of documents were reviewed and over twenty-five
depositions were taken. The parties concluded fact discovery and virtually all
expert discovery. Various discovery motions, a motion for summary judgment and
motions in limine were filed, briefed and ruled upon by the Court.

         g. On or about September 15, 2000, Lead Plaintiffs filed their motion
for class certification, which was unopposed by Defendants. On November 6, 2000,
the Court granted Lead Plaintiffs' motion for class certification, and
certified, pursuant to Fed. R. Civ. P. 23(a) and (b)(3), a class consisting of:
all persons who purchased Pediatrix Medical Group, Inc. common stock, purchased
Pediatrix call options, or sold Pediatrix put options between March 31,1997 and
April 2, 1999, inclusive. Excluded from the Class are Pediatrix, its
subsidiaries and affiliates, the Individual Defendants, members of the immediate
families of each of the Individual Defendants, and any entities in which any of
the Defendants has a controlling interest, and the legal representatives, heirs,
successors, affiliates or assigns of any of the foregoing excluded persons and
entities. On or about May 23, 2001, the Court approved the proposed Notice of
Pendency of Class Action to the Class and the Summary Notice of Pendency of

                                       3
<PAGE>

Class Action for publication. Notice of class certification was provided to
Class members in accordance with the provisions of the May 23, 2001 Order.

         h. A Joint Pretrial Stipulation was filed on or about September 1,
2001, a pretrial conference was held with the Court on November 19, 2001 and
trial of this action was scheduled to commence on January 14, 2002.

         i. On or about December 13, 2001, the parties entered into a Memorandum
of Understanding ("MOU"), memorializing their agreement in principle to settle
the Action, subject to Court approval, on the terms set forth therein. Among
other things, the MOU provides that Defendants shall pay or cause to be paid to
the Class, in settlement of the claims against them, the sum of $12,000,000
(twelve million dollars), to be deposited into an interest bearing account
designated by Co-Lead Counsel within ten (10) business days of preliminary
approval of the Stipulation, or ten (10) business days after Lead Plaintiffs
furnish payment instructions for the settlement account to Defendants' counsel,
whichever occurs last. In exchange for this consideration, Lead Plaintiffs
agreed, upon final approval of the Settlement, to dismiss the Action with
prejudice and to release all claims, known and unknown, arising out of the
purchase or acquisition of Pediatrix common stock and Pediatrix call options and
the sale of Pediatrix put options during the Class Period and relating to the
allegations of the Complaint, which have been or could have been asserted by any
member of the Class in the Action against the Defendants and various other
related parties. Defendants agreed to release Plaintiffs, the members of the
Class and their counsel from any claims relating to the institution, prosecution
or settlement of the Action.

                                       4
<PAGE>

         j. Defendants deny any wrongdoing whatsoever and this Stipulation shall
in no event be construed or deemed to be evidence of or an admission or
concession on the part of any Defendant with respect to any claim of any fault
or liability or wrongdoing or damage whatsoever, or any infirmity in the
defenses that Defendants could have asserted. Defendants assert that they
complied with all applicable laws and regulations and deny that they have
committed any act or omission giving rise to any liability and/or violation of
law and state that they are entering into this Settlement to eliminate the
burden and expense of further litigation.

         k. Lead Plaintiffs' Co-Lead Counsel conducted an investigation relating
to the claims and the underlying events and transactions alleged in the
Complaint and assert that the allegations they pursued in this Action are
meritorious. Among other things, Lead Plaintiffs' Co-Lead Counsel analyzed the
public records and evidence adduced during pretrial discovery and researched the
applicable law with respect to the claims of Lead Plaintiffs and the other
members of the Class against Defendants and the potential defenses thereto.

         l. Lead Plaintiffs, with and through their counsel, conducted
discussions and arms'-length negotiations, including mediations, with counsel
for and representatives of Defendants to determine if the Action could be
compromised and settled achieving the best relief possible consistent with the
interests of the Class.

         m. Based on their investigation and pretrial discovery as set forth
above, Lead Plaintiffs and their counsel have concluded that the terms and
conditions of this Stipulation are fair, reasonable and adequate to Lead
Plaintiffs and the other members of the Class, and in their best interests, and
have agreed to settle the claims raised in the Action pursuant to the terms and
provisions of this Stipulation, after considering (a) the substantial benefits
that Lead Plaintiffs and the other members of the Class will receive from
settlement of the Action, (b) the attendant

                                       5
<PAGE>

risks of continued litigation, especially in complex actions such as this
Action, as well as the difficulties and delays inherent in such litigation, and
(c) the desirability of permitting the Settlement to be consummated as provided
by the terms of this Stipulation.

         NOW THEREFORE, without any admission or concession on the part of Lead
Plaintiffs of any lack of merit of the Action whatsoever, and without any
admission or concession of any liability or wrongdoing or lack of merit in the
defenses whatsoever by Defendants, it is hereby

         STIPULATED AND AGREED, by and among the parties to this Stipulation,
through their respective attorneys, subject to approval of the Court pursuant to
Rule 23(e) of the Federal Rules of Civil Procedure, in consideration of the
benefits flowing to the parties hereto from the Settlement, that all Released
and Settled Claims (as defined below) as against the Released Parties (as
defined below) and all Released and Settled Defendants' Claims (as defined
below) shall be compromised, settled, released and dismissed with prejudice,
upon and subject to the following terms and conditions:

                              CERTAIN DEFINITIONS

         1. As used in this Stipulation, the following terms shall have the
following meanings:

                  (1) "Class" and "Class Members" means Lead Plaintiffs and all
other persons or entities who purchased the common stock of Pediatrix or
purchased Pediatrix call options or sold Pediatrix put options during the period
between March 31, 1997 and April 2, 1999, inclusive (the "Class Period").
Excluded from the Class are Defendants herein and the members of the Individual
Defendants' immediate families, any entity in which any Defendant has a
controlling interest or is a parent or subsidiary of or is controlled by any
Defendant, and their legal representatives, heirs, affiliates, successors and
assigns of any of the excluded persons or entities.

                                       6
<PAGE>

Also excluded from the Class are any putative Class Members who excluded
themselves by filing a request for exclusion in accordance with the requirements
set forth in the Notice of Pendency of Class Action.

                  (2) "Authorized Claimant" means a Class Member who submits a
timely and valid Proof of Claim form to the Claims Administrator.

                  (3) "Class Period" means the period of time between March 31,
1997 and April 2, 1999, inclusive.

                  (4) "Complaint" means the Second Consolidated Amended Class
Action Complaint filed on or about February 3, 2000.

                  (5) "Effective Date of Settlement" or "Effective Date" means
the date upon which the Settlement contemplated by this Stipulation shall become
effective, as set forth in ss.23 below.

                  (6) "Defendants" means Pediatrix Medical Group, Inc., Roger J.
Medel, Karl B. Wagner and Lawrence M. Mullen.

                  (7) "Defendants' Counsel" means the law firms of Davis Polk &
Wardwell and Hunton & Williams.

                  (8) "Individual Defendants" means Roger J. Medel, Karl B.
Wagner and Lawrence M. Mullen.

                  (9) "Notice" means the Notice of Proposed Settlement of Class
Action, Settlement Fairness Hearing, and Right to Share in Settlement Fund,
which is to be sent to members of the Class substantially in the form attached
hereto as Exhibit 1 to Exhibit A.

                  (10) "Order and Final Judgment" means the proposed order to be
entered approving the Settlement substantially in the form attached hereto as
Exhibit B.

                                       7
<PAGE>

                  (11) "Order for Preliminary Approval of Settlement" means the
proposed Preliminary Order in Connection with Settlement Proceedings
preliminarily approving the Settlement and directing notice thereof to the Class
substantially in the form attached hereto as Exhibit A.

                  (12) "Plaintiffs" means the Lead Plaintiffs, Jacksonville
Police & Fire Pension Fund, and all of the non-lead plaintiffs named in the
Complaint.

                  (13) "Plaintiffs' Counsel" means Plaintiffs' Co-Lead Counsel
and all other counsel appearing on the Complaint.

                  (14) "Plaintiffs' Co-Lead Counsel" means the law firms of
Berman DeValerio Pease Tabacco Burt & Pucillo and Bernstein Litowitz Berger &
Grossmann LLP.

                  (15) "Publication Notice" means the Summary Notice of Proposed
Settlement and Settlement Hearing for publication substantially in the form
attached as Exhibit 3 to Exhibit A.

                  (16) "Recognized Claim" means the amount of an Authorized
Claimant's loss that is determined by the Claims Administrator to be compensable
under the Plan of Allocation.

                  (17) "Released Parties" means Pediatrix, the Individual
Defendants, and each of their past or present subsidiaries, parents, successors,
predecessors, insurers, reinsurers, officers, directors, shareholders,
employees, agents, advisors, investment advisors, attorneys, auditors,
accountants, heirs, beneficiaries, and any person, firm, trust, corporation,
officer, director or other individual or entity in which any Defendant has a
controlling interest or which is related to or affiliated with any of the
Defendants and the legal representatives, heirs, successors in interests or
assigns of the Defendants.

                                       8
<PAGE>

                  (18) "Released and Settled Claims" means any and all claims,
rights or causes of action or liabilities whatsoever, whether based on federal,
state, local, statutory or common law or any other law, rule or regulation,
including both known and Unknown Claims, that have been or could have been or
could be asserted in any forum by Plaintiffs or any of the other Class Members
against any of the Released Parties which arise out of or relate in any way to
the following during the Class Period: (1) the purchase of Pediatrix common
stock; the purchase of Pediatrix call options; or the sale of Pediatrix put
options; and (2) the allegations, transactions, facts, matters or occurrences,
representations or omissions involved, set forth or referred to in the
Complaint.

                  (19) "Released and Settled Defendants' Claims" means any and
all claims, rights or causes of action or liabilities whatsoever, whether based
on federal, state, local, statutory or common law or any other law, rule or
regulation, including both known and Unknown Claims that have been or could be
asserted in any forum by Pediatrix and the Individual Defendants, the Released
Parties or any of them or the successors and assigns of any of them against any
of the Plaintiffs, the Jacksonville Police & Fire Pension Fund, other Class
Members or their attorneys, which arise out of or relate in any way to the
institution or prosecution of the Action.

                  (20) "Settlement" means the settlement contemplated by this
Stipulation.

                  (21) "Claims Administrator" means The Garden City Group, Inc.,
selected by Plaintiffs' Co-Lead Counsel subject to approval of the Court which
shall administer the Settlement.

                  (22) "Unknown Claims" means any and all Released and Settled
Claims which any Lead Plaintiff or other Class Member does not know or suspect
to exist in his, her or its

                                       9
<PAGE>

favor at the time of the release of the Released Parties, and any Released and
Settled Defendants' Claims which any Defendant does not know or suspect to exist
in his or its favor, which if known by him or it might have affected his or its
decision(s) with respect to the Settlement. With respect to any and all Released
and Settled Claims and Released and Settled Defendants' Claims, the parties
stipulate and agree that, upon the Effective Date, Lead Plaintiffs and
Defendants shall expressly, and each Class Member shall be deemed to have, and
by operation of the Order and Final Judgment shall have, expressly waived any
and all provisions, rights and benefits conferred by any law of any state or
territory of the United States, or principle of common law, which is similar,
comparable, or equivalent to Cal. Civ. Code ss. 1542, which provides:

                  A general release does not extend to claims which the creditor
                  does not know or suspect to exist in his favor at the time of
                  executing the release, which if known by him must have
                  materially affected his settlement with the debtor.

Plaintiffs and the Defendants acknowledge, and the other Class Members by
operation of law shall be deemed to have acknowledged, that the inclusion of
"Unknown Claims" in the definition of Released and Settled Claims and Released
and Settled Defendants' Claims was separately bargained for and each was a key
element of the Settlement.

SCOPE AND EFFECT OF SETTLEMENT

         2. The obligations incurred pursuant to this Stipulation shall be in
full and final disposition of the Action and any and all Released and Settled
Claims as against all Released Parties and any and all Released and Settled
Defendants' Claims.

         3. (1) By operation of the Order and Final Judgment, upon the Effective
Date of this Settlement, Lead Plaintiffs and the other members of the Class on
behalf of themselves, their heirs, executors, administrators, successors and
assigns, and any persons they represent, shall,

                                       10
<PAGE>

with respect to each and every Released and Settled Claim, release and forever
discharge, and shall forever be enjoined from prosecuting, any Released and
Settled Claims against any of the Released Parties.

            (2) By operation of the Order and Final Judgment, upon Effective
Date of this Settlement, Pediatrix and each Individual Defendant, on behalf of
himself, his executor, administrator and the Released Parties, shall release and
forever discharge each and every of the Released and Settled Defendants' Claims,
and shall forever be enjoined from prosecuting any Released and Settled
Defendants' Claims.

THE SETTLEMENT CONSIDERATION

         4. (1) Defendants shall deposit or cause to be deposited within ten
(10) business days of entry of the Order for Preliminary Approval of Settlement
or within ten (10) business days after Lead Plaintiffs furnish payment
instructions for the Settlement Account to Defendants' Counsel, whichever last
occurs, the total sum of $12,000,000 by wire transfer or check into an
interest-bearing escrow account (the "Settlement Amount" or "Settlement Fund").

            (2) The Settlement Amount and any interest earned thereon shall be
the Gross Settlement Fund. The Gross Settlement Fund, net of any Taxes (as
defined below) on the income thereof, shall be used to pay (i) the Notice and
Administration Costs referred to in P. 7 hereof, (ii) the attorneys' fee and
expense award referred to in P. 8 hereof, (iii) the remaining administration
expenses referred to in P. 11 hereof. The balance of the Gross Settlement Fund
after the above payments shall be the Net Settlement Fund that shall be
distributed to the Authorized Claimants as provided in P. P. 12-14 hereof. Any
sums required to be held in escrow prior to the Effective Date shall be held by
Plaintiffs' Co-Lead Counsel as Escrow Agents for the Settlement Fund. All funds
held by the Escrow Agents shall be deemed to be in the custody of the Court and
shall remain subject to the jurisdiction of the Court until such time as the
funds

                                       11
<PAGE>

shall be distributed or returned to Defendants pursuant to this Stipulation
and/or further order of the Court. The Escrow Agents shall invest any funds in
excess of $100,000 in short term United States Agency or Treasury Securities,
and shall collect and reinvest all interest accrued thereon. Any funds held in
escrow in an amount of less than $100,000 may be held in an interest-bearing
account insured by the FDIC. The parties hereto agree that the Settlement Fund
is intended to be a Qualified Settlement Fund within the meaning of Treasury
Regulation ss. 1.468B2(k)(3), Plaintiffs' Co-Lead Counsel shall be responsible
for filing tax returns for the Settlement Fund and paying from the Settlement
Fund any Taxes owed with respect to the Settlement Fund. Plaintiffs' Co-Lead
Counsel shall indemnify and hold harmless the Released Parties for any liability
for Taxes or Tax Expense. Counsel for Defendants agree to provide promptly to
the Escrow Agents the statement described in Treasury Regulations ss.
1.468B3(e).

         5. All (i) taxes on the income of the Settlement Fund, and (ii)
expenses and costs incurred in connection with the taxation of the Settlement
Fund (including, without limitation, expenses of tax attorneys and accountants)
(collectively "Taxes") shall be paid out of the Settlement Fund, shall be
considered to be a cost of administration of the Settlement and shall be timely
paid by the Escrow Agents without prior Order of the Court. The Escrow Agents
shall inform counsel for Defendants of such tax payments.

ADMINISTRATION

         6. The Claims Administrator shall administer the Settlement under
Plaintiffs' Co-Lead Counsel's supervision and subject to the jurisdiction of the
Court. Defendants and their counsel shall have no role in or responsibility for
administering the Settlement, reviewing or challenging claims submitted, and
shall have no liability to the Class in connection with such administration.
Defendants and their counsel shall cooperate in the administration of the
Settlement to the extent reasonably necessary to effectuate its terms. Defendant
Pediatrix shall promptly provide or

                                       12
<PAGE>

cause to be provided to the claims administrator any information in its
possession or control needed to assist the claims administrator in providing
Notice to the Class.

         7. Prior to the Effective Date, Plaintiffs' Co-Lead Counsel may expend
from the Settlement Fund, without further approval from Defendants or the Court,
up to $100,000 to pay the reasonable costs and expenses associated with the
administration of the Settlement, including without limitation, the costs of
identifying members of the Class and effecting mail Notice and Publication
Notice. Such amounts shall include, without limitation, the actual costs of
publication, printing and mailing the Notice, reimbursements to nominee owners
for forwarding Notice to their beneficial owners, and the administrative
expenses incurred and fees charged by the Claims Administrator in connection
with providing Notice and processing the submitted claims.

ATTORNEYS' FEES AND EXPENSES

         8. Plaintiffs' Co-Lead Counsel, on behalf of all Plaintiffs' Counsel,
will apply to the Court for an award from the Gross Settlement Fund of
attorneys' fees and reimbursement of expenses. Such attorneys' fees, expenses
and costs, including the fees of experts and consultants, as awarded by the
Court ("Fee and Expense Award"), shall be paid from the Gross Settlement Fund to
Plaintiffs' Co-Lead Counsel, as ordered, immediately upon the District Court's
entry of the Order and Final Judgment substantially in the form attached hereto
as Exhibit B and approval of an award of fees and expenses. Plaintiffs' Co-Lead
Counsel shall thereafter be responsible for allocating the attorneys' fees
amongst all Plaintiffs' Counsel. In the event that the Effective Date does not
occur, or the Order and Final Judgment or the Fee and Expense Award is reversed
or modified in a material respect, or the Stipulation is cancelled or terminated
for any other reason, and in the event that the Fee and Expense Award has been
paid to any extent, then each Plaintiffs' Counsel shall within five (5) business
days from receiving

                                       13
<PAGE>

notice from Defendants' Counsel, or from a court of appropriate jurisdiction,
refund to the Gross Settlement Fund, the fees, expenses and costs previously
paid to them from the Gross Settlement Fund plus interest thereon at the same
rate as earned on the Gross Settlement Fund in an amount consistent with such
reversal or modification. The award of attorneys' fees is not a necessary term
of this Stipulation and it is not a condition of this Stipulation that
Plaintiffs' Co-Lead Counsel petition for fees and expenses be approved by the
Court.

         9. The procedure for and the allowance or disallowance by the Court of
any application by Plaintiffs' Co-Lead Counsel for attorneys' fees, costs and
expenses to be paid out of the Gross Settlement Fund, are not part of the
Settlement set forth in this Stipulation, and are to be considered by the Court
separately from the Court's consideration of the fairness, reasonableness and
adequacy of the Settlement set forth in this Stipulation, and any order or
proceedings relating to the fee and expense application, or any appeal from any
order relating thereto or reversal or modification thereof, shall not operate to
terminate or cancel this Stipulation, or affect or delay the finality of the
Order and Final Judgment approving this Stipulation, the Effective Date, or the
Settlement of the Action set forth herein.

         10. Defendants and their counsel shall have no responsibility for, and
no liability whatsoever with respect to the allocation amongst Plaintiffs'
Counsel, and/or any other person who may assert some claim thereto, of any Fee
and Expense Award that the Court may make in the Action. Defendants will take no
position with respect to Plaintiffs' Co-Lead Counsel's application for
attorneys' fees and reimbursement of expenses.

ADMINISTRATION EXPENSES

         11. Plaintiffs' Co-Lead Counsel will apply to the Court, on notice to
Defendants' Counsel for an order (the "Class Distribution Order") approving the
Claims Administrator's administrative determinations concerning the acceptance
and rejection of the claims submitted

                                       14
<PAGE>

herein and approving any fees and expenses not previously applied for, including
the fees and expenses of the Claims Administrator, determining that the
Effective Date has occurred and directing payment of the Net Settlement Fund to
Authorized Claimants.

DISTRIBUTION TO AUTHORIZED CLAIMANTS

         12. The Claims Administrator shall determine each Authorized Claimant's
pro rata share of the cash in the "Net Settlement Fund" (as defined in P. 4
hereof) based upon each Authorized Claimant's Recognized Claim (as defined in
the Plan of Allocation described in the Notice annexed hereto as Exhibit 1 to
Exhibit A, or in such other Plan of Allocation as the Court approves).

         13. The Plan of Allocation proposed in the Notice is not a necessary
term of this Stipulation and it is not a condition of this Stipulation that that
Plan of Allocation be approved. Defendants will not have any responsibility for
nor any involvement with the Plan of Allocation and will take no position with
respect to such proposed Plan of Allocation or such plan as may be approved by
the Court.

         14. Each Authorized Claimant shall be allocated a pro rata share of the
cash in the Net Settlement Fund based on his, her or its Recognized Claim
compared to the total Recognized Claims of all Authorized Claimants. This is not
a claims made settlement. Defendants will have no ability to get back any of the
settlement monies once the Effective Date occurs. Defendants will have no
involvement in reviewing or challenging claims.

ADMINISTRATION OF THE SETTLEMENT

         15. Plaintiffs' Co-Lead Counsel shall be responsible for supervising
the administration of the Settlement and disbursement of the Net Settlement Fund
by the Claims Administrator. Except for their obligation to pay the Settlement
Amount, Defendants and their counsel shall have no liability, obligation or
responsibility for the administration of the Settlement or

                                       15
<PAGE>

disbursement of the Net Settlement Fund. Plaintiffs' Co-Lead Counsel shall have
the right, but not the obligation, to waive what they deem to be formal or
technical defects in any Proof of Claim submitted in the interest of achieving
substantial justice.

         16. For purposes of determining the extent, if any, to which a Class
Member shall be entitled to be treated as an "Authorized Claimant", the
following conditions shall apply:

                  (1) Each Class Member shall be required to submit a Proof of
Claim (substantially in the form attached as Exhibit 2 to Exhibit A), supported
by such documents as are designated therein, including proof of the Claimant's
loss, or such other documents or proof as Plaintiffs' Co-Lead Counsel, in their
discretion, may deem acceptable;

                  (2) All Proofs of Claim must be submitted by the date
specified in the Notice unless such period is extended by Order of the Court.
Any Class Member who fails to submit a Proof of Claim by such date shall be
forever barred from receiving any payment pursuant to this Stipulation (unless,
by Order of the Court, a later submitted Proof of Claim by such Class Member is
approved), but shall in all other respects be bound by all of the terms of this
Stipulation and the Settlement including the terms of the Order and Final
Judgment to be entered in the Action and the releases provided for herein, and
will be barred from bringing any action against the Released Parties concerning
the Released and Settled Claims. Provided that it is actually received no later
than thirty (30) days after the final date for submission of Proofs of Claim, a
Proof of Claim shall be deemed to have been submitted when posted, if received
with a postmark indicated on the envelope and if mailed first-class postage
prepaid and addressed in accordance with the instructions thereon. In all other
cases, the Proof of Claim shall be deemed to have been submitted when actually
received by Plaintiffs' Co-Lead Counsel or their designee;

                                       16
<PAGE>

                  (3) Each Proof of Claim shall be submitted to and reviewed by
the Claims Administrator, under the supervision of Plaintiffs' Co-Lead Counsel,
who shall determine in accordance with this Stipulation the extent, if any, to
which each claim shall be allowed, subject to review by the Court pursuant to
subparagraph (5) below;

                  (4) Proofs of Claim that do not meet the filing requirements
may be rejected. Prior to rejection of a Proof of Claim, the Claims
Administrator shall communicate with the Claimant in order to afford him, her or
it the opportunity to remedy any curable deficiencies in the Proof of Claim
submitted. The Claims Administrator, under supervision of Plaintiffs' Co-Lead
Counsel, shall notify, in a timely fashion and in writing, all Claimants whose
Proofs of Claim they propose to reject in whole or in part, setting forth the
reasons therefor, and shall indicate in such notice that the Claimant whose
claim is to be rejected has the right to a review by the Court if the Claimant
so desires and complies with the requirements of subparagraph (5) below;

                  (5) If any Claimant whose claim has been rejected in whole or
in part desires to contest such rejection, the Claimant must, within twenty (20)
days after the date of mailing of the notice required in subparagraph (4) above,
serve upon the Claims Administrator a notice and statement of reasons indicating
the Claimant's grounds for contesting the rejection along with any supporting
documentation, and requesting a review thereof by the Court. If a dispute
concerning a claim cannot be otherwise resolved, Plaintiffs' Co-Lead Counsel
shall thereafter present the request for review to the Court; and

                  (6) The administrative determinations of the Claims
Administrator accepting and rejecting claims shall be presented to the Court, on
notice to Defendants' Counsel for approval by the Court in the Class
Distribution Order.

                                       17
<PAGE>

         17. Each Claimant shall be deemed to have submitted to the jurisdiction
of the Court with respect to the Claimant's claim, and the claim will be subject
to investigation and discovery under the Federal Rules of Civil Procedure,
provided that such investigation and discovery shall be limited to that
Claimant's status as a Class Member and the validity and amount of the
Claimant's claim. No discovery shall be allowed on the merits of the Action or
the Settlement in connection with processing of the Proofs of Claim.

         18. Payment pursuant to this Stipulation shall be deemed final and
conclusive against all Class Members. All Class Members who do not submit a
claim or whose claims are not approved by the Court shall be barred from
participating in distributions from the Net Settlement Amount, but otherwise
shall be bound by all of the terms of this Stipulation and the Settlement,
including the terms of the Order and Final Judgment to be entered in the Action
and the releases provided for herein, and will be barred from bringing any
action against the Released Parties concerning the Released and Settled Claims.

         19. All proceedings with respect to the administration, processing and
determination of claims described in this Stipulation and the determination of
all controversies relating thereto, including disputed questions of law and fact
with respect to the validity of claims, shall be subject to the jurisdiction of
the Court.

         20. The Net Settlement Amount shall be distributed to Authorized
Claimants by the Claims Administrator only after the Effective Date and after:
(i) all Claims have been processed, and all Claimants whose claims have been
rejected or disallowed, in whole or in part, have been notified and provided the
opportunity to be heard concerning such rejection or disallowance; (ii) all
objections with respect to all rejected or disallowed claims not otherwise
resolved, have been resolved by the Court, and all appeals therefrom have been
resolved or the time therefore has

                                       18
<PAGE>

expired; (iii) all matters with respect to attorneys' fees, costs, and
disbursements have been resolved by the Court, all appeals therefrom have been
resolved or the time therefor has expired, and (iv) all costs of administration
and Taxes on the Settlement Fund have been paid.

TERMS OF ORDER FOR PRELIMINARY APPROVAL OF SETTLEMENT

         21. Concurrently with their application for preliminary Court approval
of the Settlement contemplated by this Stipulation, Plaintiffs' Co-Lead Counsel
and the Defendants' Counsel jointly shall apply to the Court for entry of an
Order for Preliminary Approval of Settlement, substantially in the form annexed
hereto as Exhibit A.

TERMS OF ORDER AND FINAL JUDGMENT

22. If the Settlement contemplated by this Stipulation is approved by the Court,
counsel for the parties shall request that the Court enter the Order and Final
Judgment substantially in the form annexed hereto as Exhibit B.

EFFECTIVE DATE OF SETTLEMENT, WAIVER OR TERMINATION

         23. The Effective Date of Settlement shall be the date when all the
following shall have occurred:

                  (1) Entry of the Order for Preliminary Approval of Settlement
in all material respects in the form annexed hereto as Exhibit A;

                  (2) Approval by the Court of the Settlement;

                  (3) Entry by the Court of the Order and Final Judgment, in all
material respects in the form set forth in Exhibit B annexed hereto, and the
expiration of any time for appeal or review of so much of the Order and Final
Judgment as approves the fairness, reasonableness and adequacy of the
Settlement, or, if any such appeal is filed and not dismissed, after the
approval of the fairness, reasonableness and adequacy of the Settlement is
upheld on appeal and is no longer subject to review upon appeal or review by
writ of certiorari, or, in the

                                       19
<PAGE>

event that the Court enters an order and final judgment in form other than that
provided above ("Alternative Judgment") and none of the parties hereto elect to
terminate this Settlement pursuant to P. 24, the date that such Alternative
Judgment becomes final and no longer subject to appeal or review. The Effective
Date shall not be delayed by any modification of or appeal from those parts of
the Order and Final Judgment that pertain to either the Plan of Allocation or
the award of attorneys' fees and expenses.

         24. Defendants' Counsel with the consent of their insurers or
Plaintiffs' Co-Lead Counsel shall have the right to terminate the Settlement and
this Stipulation by providing written notice of their election to do so
("Termination Notice") to all other parties hereto within thirty (30) days of
(a) the Court's declining to enter the Order for Preliminary Approval of
Settlement in any material respect; (b) the Court's refusal to approve this
Stipulation or any material part of it; (c) the Court's declining to enter the
Order and Final Judgment in any material respect; (d) the date upon which the
Order and Final Judgment is modified or reversed in any material respect by the
Court of Appeals or the Supreme Court; or (e) the date upon which an Alternative
Judgment is modified or reversed in any material respect by the Court of Appeals
or the Supreme Court.

         25. Except as otherwise provided herein, in the event the Settlement is
terminated or modified in any material respect or fails to become effective for
any reason, then the parties to this Stipulation shall be deemed to have
reverted to their respective status in the Action as of the date and time
immediately prior to the execution of the MOU and, except as otherwise expressly
provided, the parties shall proceed in all respects as if the MOU and this
Stipulation and any related orders had not been entered, and any portion of the
Settlement Amount previously paid by or on behalf of Defendants, together with
any interest earned thereon, less any Taxes due with respect to such income, and
less costs of administration and notice actually incurred and paid or

                                       20
<PAGE>

payable from the Settlement Amount (not to exceed $100,000 without the prior
approval of Defendants and the Court), shall be returned to Defendants or their
insurers paying the same within ten (10) business days from receiving Notice
from the Defendants' Counsel.

 NO ADMISSION OF WRONGDOING

         26. This Stipulation, whether or not consummated, and any proceedings
taken pursuant to it:

                  (1) Shall not be offered or received against Defendants as
evidence of or construed as or deemed to be evidence of any presumption,
concession or admission by any Defendant of the truth of any fact alleged by
Lead Plaintiffs or the validity of any claim that had been or could have been
asserted in the Action or in any litigation, or the deficiency of any defense
that has been or could have been asserted in the Action or in any litigation, or
of any liability, negligence, fault, or wrongdoing of any Defendant;

                  (2) Shall not be offered or received against any Defendant as
evidence of a presumption, concession or admission of any fault,
misrepresentation or omission with respect to any statement or written document
approved or made by any Defendant, or against the Lead Plaintiffs, Jacksonville
Police & Fire Pension Fund, and the other members of the Class as evidence of
any infirmity in the claims of Lead Plaintiffs, Jacksonville Police & Fire
Pension Fund, and the other members of the Class;

                  (3) Shall not be offered or received against Defendants as
evidence of a presumption, concession or admission of any liability, negligence,
fault or wrongdoing, or in any way referred to for any other reason as against
any of the parties to this Stipulation, in any other civil, criminal or
administrative action or proceeding, other than such proceedings as may be
necessary to effectuate the provisions of this Stipulation; provided, however,
that if this

                                       21
<PAGE>

Stipulation is approved by the Court, Defendants may refer to it to effectuate
the liability protection granted them hereunder;

                  (4) Shall not be construed against Defendants or Lead
Plaintiffs, Jacksonville Police & Fire Pension Fund, and the other members of
the Class as an admission or concession that the consideration to be given
hereunder represents the amount which could be or would have been recovered
after trial; and

                  (5) Shall not be construed as or received in evidence as an
admission, concession or presumption against Lead Plaintiffs, Jacksonville
Police & Fire Pension Fund, or the other members of the Class or any of them
that any of their claims are without merit or that damages recoverable under the
Complaint would not have exceeded the Settlement Amount.

MISCELLANEOUS PROVISIONS

         27. All of the exhibits attached hereto are hereby incorporated by
reference as though fully set forth herein.

         28. The parties to this Stipulation intend the Settlement to be a final
and complete resolution of all disputes asserted or which could be asserted by
the Class Members against the Released Parties with respect to the Released and
Settled Claims. Accordingly, Lead Plaintiffs and Defendants agree not to assert
in this action that the litigation was brought or defended in bad faith or
without a reasonable basis. The parties hereto stipulate that the complaints,
amended complaints, dispositive motions and responsive pleadings were all filed
with evidentiary support and consistent with existing law. Accordingly, the
parties shall assert no claims of any violation of Rule 11 of the Federal Rules
of Civil Procedure relating to the prosecution or defense of the Action. The
parties agree that the amount paid and the other terms of the Settlement were
negotiated at arm's-length in good faith by the parties, and reflect a
settlement that was reached voluntarily after consultation with experienced
legal counsel.

                                       22
<PAGE>

         29. Plaintiffs agree that neither they nor their counsel will
voluntarily use, or provide or disclose in any other proceeding or to any third
party any materials obtained from Defendants or third parties in this
litigation, or any reports or other writings based on such materials.

         30. Upon the Effective Date of the Settlement, Plaintiffs' Co-Lead
Counsel, at their option, shall either destroy or return to counsel for
Defendants (at Defendants' expense) all documents and other materials produced
by Defendants and any third parties in discovery from this litigation in the
possession of Plaintiffs' Co-Lead Counsel except for those documents which are
deposition and trial exhibits.

         31. This Stipulation may not be modified or amended, nor may any of its
provisions be waived except by a writing signed by all parties hereto or their
successors-in-interest.

         32. The headings herein are used for the purpose of convenience only
and are not meant to have legal effect.

         33. The administration and consummation of the Settlement as embodied
in this Stipulation shall be under the authority of the Court and the Court
shall retain jurisdiction for the purpose of entering orders providing for
awards of attorneys' fees and expenses to Lead Plaintiffs' counsel and enforcing
the terms of this Stipulation.

         34. The waiver by one party of any breach of this Stipulation by any
other party shall not be deemed a waiver of any other prior or subsequent breach
of this Stipulation.

         35. This Stipulation and its exhibits constitute the entire agreement
among the parties hereto concerning the Settlement of the Action, and no
representations, warranties, or inducements have been made by any party hereto
concerning this Stipulation and its exhibits other than those contained and
memorialized in such documents.

                                       23
<PAGE>

         36. This Stipulation may be executed in one or more counterparts. All
executed counterparts and each of them shall be deemed to be one and the same
instrument provided that counsel for the parties to this Stipulation shall
exchange among themselves original signed counterparts.

         37. This Stipulation shall be binding upon, and inure to the benefit
of, the successors and assigns of the parties hereto.

         38. The construction, interpretation, operation, effect and validity of
this Stipulation, and all documents necessary to effectuate it, shall be
governed by the internal laws of the State of Florida without regard to
conflicts of laws, except to the extent that federal law requires that federal
law govern.

         39. This Stipulation shall not be construed more strictly against one
party than another merely by virtue of the fact that it, or any part of it, may
have been prepared by counsel for one of the parties, it being recognized that
it is the result of arm's-length negotiations between the parties and all
parties have contributed substantially and materially to the preparation of this
Stipulation.

         40. All counsel and any other person executing this Stipulation and any
of the exhibits hereto, or any related settlement documents, warrant and
represent that they have the full authority to do so and that they have the
authority to take appropriate action required or permitted to be taken pursuant
to the Stipulation to effectuate its terms.

                                       24
<PAGE>

         41. Plaintiffs' Co-Lead Counsel and Defendants' Counsel agree to
cooperate fully with one another in seeking Court approval of the Order for
Preliminary Approval of Settlement, the Stipulation and the Settlement, and to
promptly agree upon and execute all such other documentation as may be
reasonably required to obtain final approval by the District Court of the
Settlement.

DATED:   February 7, 2002

HUNTON & WILLIAMS                        BERMAN DEVALERIO PEASE
                                            TABACCO BURT & PUCILLO

By: /s/ Barry Rodney Davidson            By: /s/ Michael J. Pucillo
    -------------------------------          -----------------------------------
       Barry Rodney Davidson                    Michael J. Pucillo
       1111 Brickell Avenue                     FNB:  261033
       Suite 2500                               Wendy H. Zoberman
       Miami, FL 33131-3136                     FNB:  434670
       Tel: 305/810-2500                        515 North Flagler Drive
       Fax: 305/810-2460                        Suite 1701
                                                West Palm Beach, FL 33401
       Co-Counsel for Defendants                Tel: 561/835-9400
                                                Fax: 561/835-0322

                                                Co-Lead Counsel for Plaintiffs
                                                and the Class

DAVIS POLK & WARDWELL                    BERNSTEIN LITOWITZ BERGER
                                           & GROSSMANN LLP

By: /s/ Robert F. Wise, Jr.              By: /s/ Max W. Berger
    -------------------------------          -----------------------------------
       Robert F. Wise, Jr.                      Max W. Berger
       450 Lexington Avenue                     John P. Coffey
       New York, NY  10017                      Rochelle Feder Hansen
       Tel: 212/450-4000                        1285 Avenue of the Americas
       Fax: 212/450-4800                        New York, NY 10019
                                                Tel: 212/554-1400
       Co-Counsel for Defendants                Fax: 212/554-1444

                                                Co-Lead Counsel for Plaintiffs
                                                and the Class

                                       25
<PAGE>

                             CERTIFICATE OF SERVICE

         I HEREBY CERTIFY that a true and accurate copy of the foregoing has
been furnished via Federal Express to defense counsel and via U.S. Mail to all
other counsel on the attached Service List this February 7, 2002.

                                        /s/ Wendy H. Zoberman
                                       -----------------------------------------
                                        Wendy H. Zoberman

                                       26
<PAGE>

                                    EXHIBIT A

                          UNITED STATES DISTRICT COURT
                          SOUTHERN DISTRICT OF FLORIDA

                          CASE NO. 99-6181-CIV-GONZALEZ

SANDS POINT PARTNERS, L.P.,
et al. on behalf of themselves and
all others similarly situated,

                  Plaintiffs,

vs.

PEDIATRIX MEDICAL GROUP, INC.,
ROGER J. MEDEL, KARL B. WAGNER,
and LAWRENCE M. MULLEN,

         Defendants.

-----------------------------------/

           PRELIMINARY ORDER IN CONNECTION WITH SETTLEMENT PROCEEDINGS

         WHEREAS, on or about _________________, 2002, the parties to the
above-entitled certified class action litigation (the "Action") entered into a
Stipulation and Agreement of Settlement (the "Stipulation") which is subject to
review under Rule 23 of the Federal Rules of Civil Procedure ("Fed. R. Civ. P.")
and which, together with the exhibits thereto, sets forth the terms and
conditions for the proposed settlement of the claims alleged against the
Defendants in the Second Amended Consolidated Class Action Complaint (the
"Complaint");

         WHEREAS, the Court has read and considered the Stipulation and the
accompanying documents; and the parties to the Stipulation having consented to
the entry of this Order; and all capitalized terms used herein having the
meanings defined in the Stipulation;

<PAGE>

         NOW, THEREFORE, IT IS HEREBY ORDERED, this _____ day of _____________,
2002, that:

         1. The Settlement as set forth in the Stipulation is preliminarily
approved for the purpose of sending Notice to the Class.

         2. A hearing (the "Settlement Fairness Hearing") pursuant to Fed. R.
Civ. P. 23(e) is hereby scheduled to be held before the Court on
_______________, 2002, at ________ __. M. for the following purposes:

                  (l)      to determine whether the proposed Settlement is fair,
                           reasonable, adequate and in the best interests of the
                           Class and should be approved by the Court;

                  (2)      to determine whether the Order and Final Judgment as
                           provided under the Stipulation should be entered,
                           dismissing the Complaint filed herein, on the merits
                           and with prejudice as to the Defendants;

                  (3)      to determine whether the proposed Plan of Allocation
                           for the proceeds of the Settlement is fair and
                           reasonable, and in the best interests of the Class
                           and should be approved by the Court;

                  (4)      to consider Plaintiffs' counsel's application for an
                           award of Attorneys' Fees and Expenses; and

                  (5)      to rule upon such other matters as the Court may deem
                           appropriate.

         3. The Court approves the form, substance and requirements of the
Notice of Proposed Settlement, Settlement Fairness Hearing and Right to Share in
Settlement Fund (the "Notice") and the Proof of Claim form annexed hereto as
Exhibits 1 and 2, respectively.

         4. Plaintiffs' Co-Lead Counsel shall cause the Notice and Proof of
Claim, substantially in the form annexed hereto, to be mailed, by first class
mail, postage prepaid, no

                                       2
<PAGE>

later than 20 days from the date of entry of this Order, to all Class Members
who have been identified with reasonable effort by Plaintiffs' Co-Lead Counsel
in connection with the prior mailing and publication of the Notice of Pendency
of Class Action. If necessary, Defendant Pediatrix Medical Group, Inc. shall
cooperate in making its books, records and information available to Plaintiffs'
Co-Lead Counsel or their agent for the purpose of identifying and giving notice
to the Class. Plaintiffs' Co-Lead Counsel shall use reasonable efforts to give
notice to nominee owners such as brokerage firms and other persons or entities
who purchased Pediatrix common stock during the Class Period as record owners
but not as beneficial owners. Such nominee purchasers are directed, within ten
(10) business days of receipt of the Notice and Proof of Claim, to either: (a)
provide the Claims Administrator with lists of the names and addresses of the
beneficial owners, and the Claims Administrator is ordered to send the Notice
and Proof of Claim promptly to such beneficial owners, or (b) request additional
copies of the Notice and Proof of Claim form and, within seven (7) days of
receipt of those copies, mail the Notice and Proof of Claim form directly to the
beneficial owners. Additional copies of the Notice and Proof of Claim shall be
made available free of charge to any record holder requesting such for the
purpose of distribution to beneficial owners, and such record holders shall be
reimbursed from the Settlement Fund, upon receipt by Plaintiffs' Co-Lead Counsel
of proper documentation, for the reasonable expense actually incurred in sending
the Notice and Proof of Claim to beneficial owners. If any nominee purchaser
chooses to follow alternative procedure (b), such nominee shall, upon such
mailing, send a statement to the Claims Administrator confirming that the
mailing was made as directed. Plaintiffs' Co-Lead Counsel shall, at or before
the Settlement Fairness Hearing, file with the Court proof of mailing of the
Notice and Proof of Claim.

                                       3
<PAGE>

         5. The Court approves the form of Publication Notice of the proposed
Settlement and Settlement Fairness Hearing in substantially the form and content
annexed hereto as Exhibit 3 and directs that Plaintiffs' Co-Lead Counsel shall
cause the Publication Notice to be published once in the BUSINESS WIRE and in
INVESTORS BUSINESS DAILY within ten (10) days of the mailing of the Notice.
Plaintiffs' Co-Lead Counsel shall, at or before the Settlement Fairness Hearing,
file with the Court proof of publication of the Publication Notice.

         6. The form and method set forth herein of notifying the Class of the
Settlement and its terms and conditions meet the requirements of Rule 23 of the
Federal Rule of Civil Procedure, Section 21D(a)(7) of the Exchange Act, 15
U.S.C. ss. 78u-4(1)(7) as amended by the Private Securities Litigation Reform
Act of 1995, and due process, constitute the best notice practicable under the
circumstances, and shall constitute due and sufficient notice to all persons and
entities entitled thereto.

         7. In order to be entitled to participate in the distribution of the
Net Settlement Fund, in the event the Settlement is effected in accordance with
all of the terms and conditions thereof, each Class member shall take the
following actions and be subject to the following conditions:

                  (1)      A properly executed Proof of Claim (the "Proof of
                           Claim"), substantially in the form attached hereto as
                           Exhibit 2, must be submitted to the Claims
                           Administrator, at the Post Office box indicated in
                           the Notice, not later than June 3, 2002. Such
                           deadline may be further extended by Court Order. Each
                           Proof of Claim shall be deemed to have been submitted
                           when postmarked (if properly addressed and mailed by
                           first class mail, postage prepaid) provided such
                           Proof of Claim is actually received no later than
                           thirty (30) days after the final date for submission
                           of Proofs of Claim.

                                       4
<PAGE>

                           Any Proof of Claim submitted in any other manner
                           shall be deemed to have been submitted when it was
                           actually received at the address designated in the
                           Notice.

                  (2)      The Proof of Claim filed by each Class Member must
                           satisfy the following conditions: (i) it must be
                           properly filled out, signed and submitted in a timely
                           manner in accordance with the provisions of the
                           preceding subparagraph; (ii) it must be accompanied
                           by adequate supporting documentation for the
                           transactions reported therein, in the form of broker
                           confirmation slips, broker account statements, an
                           authorized statement from the broker containing the
                           transactional information found in a broker
                           confirmation slip, or such other documentation as is
                           deemed adequate by Plaintiffs' Co-Lead Counsel; (iii)
                           if the person executing the Proof of Claim is acting
                           in a representative capacity, a certification of his
                           current authority to act on behalf of the Class
                           Member must be included in the Proof of Claim; and
                           (iv) the Proof of Claim must be complete and contain
                           no material deletions or modifications of any of the
                           printed matter contained therein and must be signed
                           under penalty of perjury.

                  (3)      As part of the Proof of Claim, each Class Member
                           shall submit to the jurisdiction of the Court with
                           respect to the claim submitted, and shall (subject to
                           effectuation of the Settlement) release all claims as
                           provided in the Stipulation.

         8. Class Members shall be bound by all determinations and judgments in
this Action, whether favorable or unfavorable, unless such persons have
requested exclusion from the

                                       5
<PAGE>

Class in a timely and proper manner, as provided in the Notice of Pendency of
Class Action previously sent to Class Members.

         9. Class Members who have requested exclusion from the Class pursuant
to the Notice of Pendency of Class Action shall not be entitled to receive any
payment out of the Net Settlement Fund as described in the Stipulation and
Notice.

         10. All Class Members may enter appearances in the Action, at their own
expense, individually or through counsel of their own choice. If they do not
enter an appearance, they will continue to be represented by Plaintiffs' Co-Lead
Counsel, Michael I. Pucillo, Esq., Berman DeValerio Pease Tabacco Burt &
Pucillo, Northbridge Centre, Suite 1701, 515 N. Flagler Drive, West Palm Beach,
FL 33401 and John P. Coffey, Esq., Bernstein Litowitz Berger & Grossmann LLP,
1285 Avenue of the Americas, 33rd Floor, New York, New York 10019.

         11. The Court will consider comments and/or objections to the
Settlement, the Plan of Allocation, or the application for an award of
attorneys' fees and reimbursement of expenses only if such comments or
objections and any supporting papers are filed in writing with the Clerk of the
Court, United States District Court, 299 East Broward Boulevard, Fort
Lauderdale, Florida 33301, and copies of all such papers are received, no later
than fourteen (14) days prior to the Settlement Fairness Hearing, by the
following: Michael J. Pucillo, Esq., Berman DeValerio Pease Tabacco Burt &
Pucillo, 515 N. Flagler Drive, Suite 1701, West Palm Beach, Florida 33401; and
John P. Coffey, Esq., Bernstein Litowitz Berger & Grossmann LLP, 1285 Avenue of
the Americas, 33rd Floor, New York, New York 10019, on behalf of Plaintiffs; and
Robert F. Wise, Jr., Esq., Davis Polk & Wardwell, 450 Lexington Avenue, New
York, NY 10017 and Barry Rodney Davidson, Esq., Hunton & Williams, 1111 Brickell
Avenue, Suite 2500, Miami, FL 33131-3136 on behalf of the Defendants. Attendance
at the hearing is not necessary;

                                       6
<PAGE>

however, persons wishing to be heard orally in opposition to the approval of the
Settlement, the Plan of Allocation, and/or the application for attorneys' fees
and reimbursement of expenses are required to indicate in their written
objection their intention to appear at the hearing. Persons who intend to object
to the Settlement, the Plan of Allocation, and/or counsel's application for an
award of attorneys' fees and expenses and desire to present evidence at the
Settlement Fairness Hearing must include in their written objections the
identity of witnesses they may call to testify and exhibits they intend to
introduce into evidence at the Settlement Fairness Hearing. Any member of the
Class who does not object in this manner shall be deemed to have waived such
objection and shall forever be foreclosed from making any objection to the
fairness or adequacy of the proposed Settlement, to any Final Judgment that may
be entered, to the Fee and Expense Award to Plaintiffs' Co-Lead Counsel, and to
the Plan of Allocation. Class Members do not need to appear at the hearing or
take any other action to indicate their approval.

         12. Only Class Members shall have any rights with respect to approval
of or objection to the Settlement, the Plan of Allocation or Plaintiffs' Co-Lead
Counsel's request for Attorneys' Fees and Expenses. Any Class Member wishing to
preserve appellate rights with respect to the Settlement or the Fee and Expense
Award to Plaintiffs' Counsel must timely intervene as a party under Rule 24 of
the Federal Rules of Civil Procedure.

         13. To assist the Court in preparing for the Settlement Fairness
Hearing, counsel may submit, no later than twenty-one (21) days prior to the
Settlement Fairness Hearing, all briefs, affidavits or other documents related
to the findings that this Court is required to make. Counsel may submit papers
in response to any objections that may be filed no later than seven (7) days
prior to the Settlement Fairness Hearing.

                                       7
<PAGE>

         14. Pending final determination of whether the Settlement should be
approved, the Plaintiffs, all other Class Members, and each of them, and anyone
who acts or purports to act on their behalf, shall not institute, commence or
prosecute any action which asserts Released and Settled Claims against any
Released Party.

         15. The Court reserves the right to adjourn or continue the date of the
Settlement Fairness Hearing with or without further notice to the Class.
However, if any Class Members indicate the intention to appear at the Settlement
Fairness Hearing in accordance with the provisions of paragraph 11 above,
Plaintiffs' Co-Lead Counsel are ordered to provide such persons with notice of
the adjourned date(s). The Court further reserves the right to enter its Order
and Final Judgment approving the Stipulation and dismissing the Complaint on the
merits and with prejudice as to the Defendants regardless of whether it has
approved the Plan of Allocation or awarded attorneys' fees and expenses.

         16. If the Settlement is disapproved, or terminated in accordance with
the terms of the Stipulation, the Stipulation shall be null and void, of no
further force or effect, and without prejudice to any party, and may not be
introduced as evidence or referred to in any actions or proceedings by any
person or entity, and each party shall be restored to his, her or its respective
position as it existed prior to the execution of the Memorandum of Understanding
and Stipulation.

         17. In the event the Settlement is disapproved or terminated in
accordance with the terms of the Stipulation, the Escrow Agent(s) shall, within
ten days of notice of disapproval or termination, refund the Settlement Fund,
plus all accrued interest thereon to the Defendants and their insurer in
proportion to their relative contributions, except for any Taxes due, Notice and
administration expenses up to $100,000.00 incurred in issuing notice to the
Class.

         18. The Court retains exclusive jurisdiction over the Action to
consider all further matters arising out of or connected with the Settlement.

                                       8
<PAGE>

         DONE AND ORDERED in Chambers at Fort Lauderdale, Broward County,
Florida, this _____ day of __________________, 2002.

                                             -----------------------------------
                                             THE HONORABLE JOSE A. GONZALEZ, JR.
                                             UNITED STATES DISTRICT JUDGE

Copies furnished to all counsel on the attached Service List

                                       9
<PAGE>

                                    EXHIBIT 1

                          UNITED STATES DISTRICT COURT
                          SOUTHERN DISTRICT OF FLORIDA

                          CASE NO. 99-6181-CIV-GONZALEZ

SANDS POINT PARTNERS, L.P., et al., on
behalf of themselves and all others similarly
situated,

                  Plaintiffs,

         -against-

PEDIATRIX MEDICAL GROUP, INC.,
ROGER J. MEDEL, KARL B. WAGNER and
LAWRENCE M. MULLEN

                  Defendants.

----------------------------------------------

            NOTICE OF PROPOSED SETTLEMENT OF CLASS ACTION, SETTLEMENT
            FAIRNESS HEARING, AND RIGHT TO SHARE IN SETTLEMENT FUND

         TO:      ALL PERSONS AND ENTITIES ("THE CLASS") WHO PURCHASED COMMON
                  STOCK OR CALL OPTIONS, OR SOLD PUT OPTIONS OF PEDIATRIX
                  MEDICAL GROUP, INC. BETWEEN MARCH 31,1997 AND APRIL 2,1999,
                  INCLUSIVE (THE "CLASS PERIOD")

         PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. YOUR RIGHTS MAY
BE AFFECTED BY PROCEEDINGS IN THIS LITIGATION. IF YOU ARE A CLASS MEMBER, YOU
ULTIMATELY MAY BE ENTITLED TO RECEIVE BENEFITS PURSUANT TO THE PROPOSED
SETTLEMENT DESCRIBED HEREIN.

CLAIMS DEADLINE: CLAIMANTS MUST SUBMIT PROOFS OF CLAIM ON THE FORM ACCOMPANYING
THIS NOTICE, POST MARKED ON OR BEFORE _______________________, 2002.

NOTICE IS HEREBY GIVEN, pursuant to Rule 23 of the Federal Rules of Civil
Procedure and an Order of the United States District Court for the Southern
District of Florida (the "Court") dated ___________________, 2002, that a
hearing will be held before the Honorable Jose A. Gonzalez, Jr. in the United
States District Courthouse, 299 East Broward Boulevard, Fort Lauderdale, Florida
33301, at _________, on ________________, 2002 (the "Settlement

<PAGE>

Hearing") to determine whether a proposed settlement (the "Settlement") of the
above-captioned litigation (the "Action") as set forth in the Stipulation and
Agreement of Settlement dated as of __________________, 2002 (the
"Stipulation"), is fair, reasonable and adequate and to consider the application
of Plaintiffs' counsel for attorneys' fees and reimbursement of expenses.

I. SUMMARY OF SETTLEMENT AND RELATED MATTERS

         A. STATEMENT OF PLAINTIFFS' RECOVERY:

         Pursuant to the Settlement described herein, a Settlement Fund
consisting of $12 million in cash plus interest has been established. Assuming
that all affected shares elected to participate in the Settlement, the average
recovery under the Settlement per damaged share of Pediatrix common stock is
estimated by Plaintiffs' damages expert at approximately $1.38 per share before
deduction of Court-awarded attorneys' fees and expenses and the costs of
administering this Settlement.1 Depending upon the number of claims filed, an
individual Class member will receive more or less than this average amount. A
Class member's distribution of the Settlement Fund will be governed by a Plan of
Allocation, as approved by the Court. A detailed explanation of the Plan of
Allocation appears in Section V of this Notice.

         B. STATEMENT OF POTENTIAL OUTCOME OF THE LITIGATION.

         The parties disagree as to both liability and damages. They do not
agree on the average amount of damages per share that would be recoverable if
Plaintiffs were to have prevailed on each claim alleged. The issues on which the
parties disagree include, among other things: (i) whether the statements made
were false or misleading or were material or otherwise actionable under the
federal securities laws; (ii) the extent to which the various matters that
Plaintiffs allege were materially false or misleading influenced (if at all) the
trading price of Pediatrix common stock and call and put options during the
Class Period; and (iii) the amount by which Pediatrix common stock and call
options and put option were so influenced (if at all) during the Class Period.
The Defendants deny that they are liable to Plaintiffs or the Class and deny
Plaintiffs or the other members of the Class have suffered any damages as the
result of the alleged wrongdoing. Plaintiffs believe the proof at trial would
show that Pediatrix's shares were consistently artificially inflated by
approximately $10.34 throughout the Class Period. Defendants disagree and assert
that there is no causal link between the losses in Pediatrix stock values and
any violations of the federal securities laws. In addition, the Defendants would
have argued at trial that the decrease in the share price experienced by
Pediatrix was attributable to other factors including a general industry decline
and market forces, and that damages would be, at most, $1.93 per share. In this
Action, as in any action, Plaintiffs' Co-Lead Counsel recognized that there was
a substantial risk that Plaintiffs and the Class might not have prevailed on any
of their claims and contentions or would have only prevailed on some of their
claims and therefore, would have recovered nothing or substantially less than
the maximum amount. Plaintiffs' Co-Lead Counsel believe that the proposed
Settlement is in the best interests of the Plaintiffs and the Class.

--------
1 No estimate is included with respect to the average recovery per call options
and put option due to the variety of call options and put options and the
difficulty in obtaining trading records for options.

                                       2
<PAGE>

         C. STATEMENT OF ATTORNEYS' FEES AND COSTS SOUGHT.

         Plaintiffs' counsel have not received any payment for their services in
conducting this Action on behalf of Plaintiffs and the other members of the
Class, nor have they been reimbursed for their out-of-pocket expenditures. If
the Settlement is approved by the Court, Plaintiffs' counsel intend to apply for
fees of up to 30% of the Settlement Fund or approximately $0.41 per damaged
share, and for reimbursement of expenses incurred in connection with the
prosecution of this Action not to exceed $__________________, or approximately
$_____________ per damaged share.

         D. THE REASONS FOR SETTLEMENT.

         Plaintiffs believe that the proposed settlement is fair, reasonable and
adequate and is in the best interests of the Class considering the amount of the
Settlement and the immediacy of recovery to the Class. At the time this
Settlement was reached, the parties were close to trial. All discovery on the
facts, including depositions, exchange of documents, and interrogatory
responses, had been completed, and the parties had exchanged reports by their
experts as to the propriety of Pediatrix's coding practices, which revealed that
the trial would involve difficult questions regarding intent, interpretation of
coding standards and a battle of experts. The amount of damages sustained by the
class, if any, would also have been a contested issue at trial. Plaintiffs
estimated that each Pediatrix share purchased during the Class Period was
damaged by $10.34, while the Defendants vigorously denied that there were any
damages caused by the Defendants, but that any provable damages would have been,
at most, $1.93 per share.

         Accordingly, Plaintiffs' decision to enter into the Settlement was made
with extensive knowledge of the facts and circumstances underlying Plaintiffs'
claims and the strengths and weaknesses of those claims. In determining to
settle the Action, Plaintiffs and Plaintiffs' Co-Lead Counsel have evaluated the
extensive discovery taken in the litigation and taken into account the
substantial expense and length of time necessary to prosecute the litigation
through trial, post-trial motions and likely appeals, taking into consideration
the significant uncertainties in predicting the outcome of this complex
litigation. Plaintiffs' counsel submit that the Settlement described herein
confers very substantial benefits upon the Class. Based upon their consideration
of all of these factors, Lead Plaintiffs and their counsel have concluded that
it is in the best interest of Plaintiffs and the Class to settle the Action on
the terms described herein.

         E. IDENTIFICATION OF PLAINTIFFS' LAWYERS.

         Further information regarding the Action and this Notice may be
obtained by contacting Co-Lead counsel for Plaintiffs and the Class:

         Michael J. Pucillo, Esq.                 John P. Coffey, Esq.
         Wendy H. Zoberman, Esq.                  Rochelle Feder Hansen, Esq.
         Berman DeValerio Pease                   Bernstein Litowitz Berger
           Tabacco Burt & Pucillo                   & Grossmann LLP
         515 N. Flagler Dr., Suite 1701           1285 Avenue of the Americas
         West Palm Beach, FL 33401                New York, NY 10019
         (561) 835-9400                           (212) 554-1400

                                       3
<PAGE>

II. BACKGROUND OF THE ACTION

         A. As previously detailed in the Notice of Pendency of Class Action,
this Action commenced on or about February 16, 1999 with the filing of a number
of class action complaints concerning the publicly traded securities of
Pediatrix (the "Pediatrix Class Actions"). The Pediatrix Class Actions alleged
violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934
(the "Exchange Act"), and Rule l0b-5 promulgated thereunder. By Order dated July
6, 1999, Florida State Board of Administration, Louisiana State Employees'
Retirement System, New Orleans Employees' Retirement System, and Jacksonville
Police & Fire Pension Fund were designated as Lead Plaintiffs pursuant to
Section 21D(a)(3)(B) of the Exchange Act (as amended)2 and the law firms of Burt
& Pucillo, LLP and Bernstein Litowitz Berger & Grossmann LLP were appointed
Co-Lead Counsel for Plaintiffs and the Class.3

         B. The operative allegations in the Action are contained in the Second
Amended Consolidated Class Action Complaint (the "Complaint"), filed in the
Action on or about February 3, 2000. In sum, the Complaint alleges, among other
things, that during the Class Period Pediatrix, a provider of physician services
to hospital-based neonatal and pediatric intensive care units, engaged in
unlawful billing practices, including billing for a higher and more costly level
of care than was called for given a patient baby's medical condition, which
practices caused Pediatrix's reported revenues, earnings and accounts receivable
for that period to be overstated thereby artificially inflating the price of
Pediatrix common stock, and that those practices were contrary to the Company's
affirmative public statements regarding its billing practices.

         C. The Complaint further alleges that the market learned of Pediatrix's
allegedly improper billing practices on April 5, 1999 when Pediatrix announced
that government officials in Arizona and Colorado were seeking billing-related
documents from the Company. The Complaint also alleges that shortly thereafter
it was disclosed that the investigations being conducted by Arizona and
Colorado, as well as another investigation being conducted by Florida, were
focused on issues of Medicaid fraud. It is also alleged that the inquiries into
Pediatrix's billing practices had a negative impact on Pediatrix's financial
results, resulting in lower revenues and earnings for the quarters following the
April 5, 1999 disclosure.

         D. In the Complaint, Lead Plaintiffs sought monetary damages on behalf
of themselves and all other members of the Class. The amount of monetary
damages, if any, awardable to the Class would have been determined at trial.

--------------------

2 On or about October 16, 2001, with the agreement of Defendants, Jacksonville
Police & Fire Pension Fund moved to withdraw as a Lead Plaintiff in the Action,
which motion was granted on or about October 29, 2001.

3 Effective July 1, 2001, the firms of Berman DeValerio & Pease, LLP, Berman
DeValerio Pease & Tabacco, P.C., and Burt & Pucillo, LLP merged their practices.
The combined firm is now known as Berman DeValerio Pease Tabacco Burt & Pucillo.

                                       4
<PAGE>

         E. On or about June 6, 2000, the Court denied Defendants' motion to
dismiss the Complaint. On or about June 26, 2000, the Defendants' Answer was
filed denying the substantive allegations of wrongdoing in the Complaint,
denying that Plaintiffs have stated a cause of action against the Defendants,
and denying that the Lead Plaintiffs and other members of the Class were
damaged.

         F. The parties thereafter commenced fact discovery. Throughout the
second half of the year 2000 and most of 2001, the parties engaged in extensive
discovery. Over 200,000 pages of documents were reviewed and over twenty-five
depositions were taken. The parties concluded fact discovery and virtually all
expert discovery. Various discovery motions, a motion for summary judgment and
motions in limine were filed, briefed and ruled upon by the Court.

         G. On November 6, 2000, the Court, pursuant to Fed. R. Civ. P. 23(a)
and (b)(3), entered an Order (the "Class Order") certifying a class consisting
of:

                  All persons who purchased Pediatrix Medical Group, Inc.
                  ("Pediatrix") common stock, purchased Pediatrix call options,
                  or sold Pediatrix put options between March 31, 1997 and April
                  2, 1999, inclusive. Excluded from the Class are Pediatrix, its
                  subsidiaries and affiliates, the Individual Defendants,
                  members of the immediate families of each of the Individual
                  Defendants, and any entities in which any of the Defendants
                  has a controlling interest, and the legal representatives,
                  heirs, successors, affiliates or assigns of any of the
                  foregoing excluded persons and entities.

         Notice of Pendency of Class Action (the "Notice of Pendency") was
mailed to all Class members who could be identified commencing on June 26, 2001
and was published over the BUSINESS WIRE and in INVESTORS BUSINESS DAILY on July
10, 2001. Any putative Class member who wished to be excluded from the Class was
required to file an exclusion request postmarked on or before August 27, 2001.
Any Class member who filed a request for exclusion in accordance with the
requirements set forth in the Notice of Pendency shall be excluded and shall not
participate in the Settlement. All other Class members will be bound by the
terms of the Settlement.

         H. A Joint Pretrial Stipulation was filed on or about September 1,
2001, a pretrial conference was held with the Court on November 19, 2001 and
trial of this action was scheduled to commence on January 14, 2002.

III. BACKGROUND OF THE SETTLEMENT

         The proposed Settlement described herein is the product of extensive
arm's-length negotiations between the parties and two mediation sessions with an
independent professional mediator for which Plaintiffs and Defendants each
conducted an in-depth analysis of their respective positions which were set
forth in their mediation statements prepared for the mediation. This Settlement
was reached one month prior to the scheduled start of the trial of this Action.

                                       5
<PAGE>

         As a result of their extensive discovery efforts, Plaintiffs' counsel
had a thorough understanding of the facts at issue in the Action. Among other
things, Plaintiffs' counsel contended that they could prove that Defendants'
unlawful billing practices during the years 1996 through 1998 caused Pediatrix's
reported revenues, earnings and accounts receivable for those three years to be
overstated and thereby artificially inflated the price of Pediatrix common
stock. They also contended that they could show that those practices were
contrary to the Company's affirmative public statements regarding its billing
practices, and that throughout the Class Period Defendants caused Pediatrix to
report impressive financial results while failing to reveal the true reason for
the Company's strong financial performance -- its improper billing practices.
Plaintiffs also believe that they could establish Defendants' SCIENTER in that
Pediatrix's policies, practices and directives regarding its billing practices
came directly from senior management and that, notwithstanding the fact that
senior management was on notice that billing practices were improper, these
practices continued until Pediatrix came under scrutiny for its billing
practices in early 1999. With respect to causation and damages, Plaintiffs
believe they could show that had Pediatrix properly coded and billed for the
services its doctors rendered, its common stock would have traded at materially
lower prices during the Class Period, and that, but for Defendants' billing
fraud, there would have been no basis for an investigation by the various
states, the revelation of which sent Pediatrix's stock into decline. Plaintiffs
were prepared to submit expert testimony as to damages attributable to the
improper billing practices alleged.

         For their part, the Defendants contended that they had good defenses to
both the liability and damages aspects of the Plaintiffs' claims. The Defendants
intended to show that the Company's prior public filings had included an express
risk disclosure that it was in a highly regulated business, that it was subject
to audit and investigation, and that if that occurred, it could have a material
adverse impact on the Company's financial condition. Defendants also intended to
show that it is not a violation of the federal securities laws to misinterpret
or misapply reimbursement codes in its billing, that Pediatrix never misstated
its financial results and has never been required to restate its financial
information, and that the interpretation of the codes upon which its billings
were based were made in good faith and supportable based on the language in the
codes as published. With respect to SCIENTER, Defendants contended that their
actions were inconsistent with any intent to defraud investors in that during
the Class Period there were no insider sales and the Company did not use its
stock to make acquisitions. With respect to causation and damages, Defendants
intended to show that most of the stock price decline occurred in February 1999
before any mention of coding issues or billing practices, that the price drop in
April 1999 upon the announcement of the State inquiries was not causally related
to Plaintiffs' allegations of improper coding and that, because of the
complexity of the overall billing formula and reimbursement schedules, even if
it were found that Pediatrix had used improper codes, the impact on revenues and
earnings, and therefore the materiality of such damages for investors, would be
virtually impossible to determine with any degree of reasonable certainty.

         By the time this Settlement was reached, the parties were close to
trial. All discovery of the facts, including depositions, exchange of documents,
and interrogatory responses, had been completed, and the parties had exchanged
reports by their experts as to the propriety and financial impact of the
allegedly wrongful practices, which revealed that the trial would involve a
battle of experts and difficult questions regarding intent, and interpretation
of coding standards.

                                       6
<PAGE>

Causation, and the amount of damages sustained by the Class, if any, would also
have been hotly contested issues at trial.

         Accordingly, the decision to enter into this Settlement was made with
extensive knowledge of the facts and circumstances underlying Plaintiffs' claims
and the strengths and weaknesses of those claims. In determining to settle the
Action, Plaintiffs' Co-Lead Counsel have evaluated the discovery undertaken in
the litigation, potential recoverable damages, and taken into account the
substantial expense and length of time necessary, to prosecute the litigation
through trial, post-trial motions and likely appeals, taking into consideration
the significant uncertainties in predicting the outcome of this complex
litigation. Plaintiffs' counsel believe that the Settlement described herein
confers substantial benefits upon the Class. Based upon their consideration of
all of these factors, the Lead Plaintiffs, three sophisticated institutional
investors, and their counsel have concluded that it is in the best interest of
Plaintiffs and the Class to settle the action on the terms described herein.

         Recognizing the uncertainty and the risk of the outcome of any
litigation, especially complex litigation such as this, and the difficulties and
risks inherent in the trial of such an action, Plaintiffs desire to settle the
claims of the Class against Defendants on the terms and conditions described
herein which provide substantial benefits to the Class. Co-Lead counsel for
Plaintiffs and the Class deem such Settlement to be fair, reasonable and
adequate to, and in the best interests of, the members of the Class.

         The Defendants have denied all averments of wrongdoing or liability in
the Litigation and all other accusations of wrongdoing or violations of law. The
Stipulation is not and shall not be construed or be deemed to be evidence or an
admission or a concession on the part of any of the Defendants of any fault or
liability or damages whatsoever, and the Defendants do not concede any infirmity
in the defenses which they have asserted or intended to assert in the Action.
The Defendants, while continuing to deny all allegations of wrongdoing or
liability whatsoever, desire to settle and terminate all existing or potential
claims against them, without in any way acknowledging any fault or liability.

         The amount of damages, if any, which Plaintiffs could prove was a
matter of serious dispute, and the Settlement's use of a Recognized Claim
formula for distributing the Settlement proceeds does not constitute a finding,
admission or concession that provable damages could be measured by the
Recognized Claim formula. No determination has been made by the Court as to
liability or the amount, if any, of damages suffered by the Class, nor on the
proper measure of any such damages. The determination of damages, like the
determination of liability, is a complicated and uncertain process, typically
involving conflicting expert opinions. The Settlement herein is providing an
immediate and substantial cash benefit and avoids the risks that liability or
damages might not have been proven at trial.

THE COURT HAS NOT FINALLY DETERMINED THE MERITS OF THE PLAINTIFFS' CLAIMS OR THE
DEFENSES THERETO. THIS NOTICE DOES NOT IMPLY THAT THERE HAS BEEN OR WOULD BE ANY
FINDING OF A VIOLATION OF THE LAW OR THAT RECOVERY COULD BE HAD IN ANY AMOUNT IF
THE ACTION WERE NOT SETTLED.

                                       7
<PAGE>

IV. TERMS OF THE SETTLEMENT

         1. In full and complete settlement of the claims which have or could
have been or could be asserted in this Action, and subject to the terms and
conditions of the Stipulation, Defendants have deposited or caused to be
deposited into an escrow account for the benefit of Plaintiffs and the Class
$12,000,000 which has been earning interest for the benefit of the Class since
_______________, 2002.

         2. Pursuant to the Settlement, and on the Effective Date, Plaintiffs
and the members of the Class on behalf of themselves, their heirs, executors,
administrators, successors and assigns, and any persons they represent, release
and forever discharge and shall forever be enjoined from prosecuting the
Released and Settled Claims (defined below) against any of the Released Parties
(defined below).

         3. "Released and Settled Claims" means any and all claims, rights or
causes of action or liabilities whatsoever, whether based on federal, state,
local statutory or common law or any law, rule or regulation, including both
known and Unknown Claims, that have been or could have been or could be asserted
in any form by Plaintiffs or any of the other Class Members against any of the
Released Parties which arise out of or relate in any way to the following during
the Class Period: (1) the purchase of Pediatrix common stock; the purchase of
Pediatrix Call Options; or the sale of Pediatrix Put Options; and (2) the
allegations, transactions, facts, matters or occurrences, representations or
omissions involved, set forth or referred to in the Complaint.

         4. "Released Parties" means Pediatrix, the Individual Defendants, and
each of their past or present subsidiaries, parents, successors, predecessors,
insurers, reinsurers, officers, directors, shareholders, employees, agents,
advisors, investment advisors, attorneys, auditors, accountants, heirs,
beneficiaries, and any person, firm, trust, corporation, officer, director or
other individual or entity in which any Defendant has a controlling interest or
which is related to or affiliated with any of the Defendants and the legal
representatives, heirs, successors in interest or assigns of the Defendants.

         5. If the Settlement is approved by the Court, all claims which have or
could have been or could be asserted in the Action against any of the Released
Parties will be dismissed with prejudice as to all Class Members, and all Class
Members shall be forever barred from prosecuting a class action or any other
action arising out of wrongs which have been or could have been or could be
alleged in this Action against any Released Party. The Settlement will become
effective at such time as Orders entered by the Court approving the Settlement
shall become final and not subject to appeal (the "Effective Date").

         6. Pursuant to the Settlement, and on the Effective Date, Pediatrix and
each Individual Defendant, on behalf of himself, his executor, administrator and
the Released Parties, shall release and forever discharge each and every of the
Released and Settled Defendant's Claims, and shall forever be enjoined from
prosecuting any Released and Settled Defendant's Claims.

                                       8
<PAGE>

         7. "Release and Settled Defendant's Claims," means any and all claims,
rights or causes of action or liabilities whatsoever, whether based on federal,
state, local, statutory or common law or any other law, rule or regulation,
including both known and Unknown Claims that have been or could be asserted in
any form by Pediatrix and the Individual Defendants, the Released Parties or any
of them or the successors and assigns of any of them against any of the
Plaintiffs, the Jacksonville Police & Fire Pension Fund, other Class Members or
their attorneys, which arise out of or relate in any way to the institution or
prosecution of the Action.

         8. Upon approval of the Settlement by the Court and upon satisfaction
of the other conditions to the Settlement, the Settlement Fund will be
distributed as follows: (A) to pay costs and expenses in connection with
providing Notice to the members of the Class and administering the Settlement on
behalf of the Class; (B) to pay Plaintiffs' counsels' attorneys fees and
reimbursement of expenses, with interest thereon (the "Fee and Expense Award"),
if and to the extent allowed by the Court; (C) to pay the reasonable costs
incurred in the preparation of any tax returns required to be filed on behalf of
the Settlement Fund as well as the taxes (and any interest and penalties
determined to be due thereon) owed by reason of the earnings of the Settlement
Fund; and (D) subject to the approval by the Court of the Plan of Allocation,
which is set forth below, the balance of the Settlement Fund (the "Net
Settlement Fund"), shall be distributed in accordance with the Plan of
Allocation to Class Members who submit valid, timely Proofs of Claim
("Authorized Claimants"). Approval of the Settlement is independent from
approval of the Plan of Allocation. Any determination with respect to the Plan
of Allocation will not affect the Settlement, if approved. Payment from the
Settlement Fund made pursuant to and in conformity with the Plan of Allocation,
in the event of Court approval, shall be final and conclusive.

V. ALLOCATION OF SETTLEMENT PROCEEDS AMONG CLASS MEMBERS

         1. The Net Settlement Fund shall be distributed pursuant to the
following Plan of Allocation to Authorized Claimants who file timely, acceptable
Proofs of Claim.

         2. Each Authorized Claimant shall be allocated a pro-rata share of the
Net Settlement Fund based on his, her or its "Recognized Claim" compared to the
total Recognized Claims of all Authorized Claimants. THE RECOGNIZED CLAIM IS NOT
THE AMOUNT OF YOUR RECOVERY. YOUR ACTUAL RECOVERY WILL BE LESS.

         3. COMMON STOCK

                  a.       With respect to SHARES OF PEDIATRIX COMMON STOCK
                           purchased on the open market during the Class Period,
                           WHICH AN AUTHORIZED CLAIMANT CONTINUED TO HOLD AS OF
                           APRIL 2, 1999 (the end of the Class Period), an
                           Authorized Claimant's Recognized Claim shall be
                           $10.34, which represents the amount of artificial
                           inflation in Pediatrix common stock as determined by
                           Plaintiffs' damages expert, times the number of
                           shares held.

                  b.       With respect to shares of common stock of Pediatrix
                           purchased and then sold during the Class Period, the
                           "Recognized Claim" shall be $0 since the artificial
                           inflation on the date of purchase was the same as the
                           artificial

                                       9
<PAGE>
                           inflation on the date of sale, meaning that any
                           decline in the value of the stock was attributable to
                           something other than the alleged fraud.

         4. CALL OPTIONS

                  a.       With respect to CALL OPTIONS TO PURCHASE SHARES OF
                           PEDIATRIX COMMON STOCK purchased during the Class
                           Period, an Authorized Claimant's "Recognized Claim"
                           shall mean the amount determined in accordance with
                           the following: for each Call Option on Pediatrix
                           common stock purchased on the open market during the
                           Class Period WHICH AN AUTHORIZED CLAIMANT CONTINUED
                           TO HOLD AS AN OPEN AND UNEXPIRED OPTION AS OF APRIL
                           2, 1999 (the end of the Class Period), the Recognized
                           Claim shall be equal to 50%4 of the price paid
                           (excluding commissions, etc.) for the Call Option(s)
                           less the amount (if any) that the Call Option was "in
                           the money" as of the close of trading on April 5,
                           1999 (the first day of trading after the end of the
                           Class Period) times the number of shares covered by
                           such Call Option(s).

                  b.       If a Call Option was exercised during the Class
                           Period to purchase Pediatrix common stock, the
                           "Recognized Claim" from such transaction shall be
                           calculated as a purchase of Pediatrix common stock
                           and the Authorized Claimant will have no "Recognized
                           Claim" with respect to the purchase of the option.
                           The date of the exercise of the option is the
                           "Purchase" date.

                  c.       No Recognized Claim shall be allowed with respect to
                           Call Option(s) purchased during the Class Period to
                           cover Call Option(s) previously sold or written by a
                           claimant.

                  d.       With respect to Call Option(s) purchased and then
                           sold during the Class Period, the "Recognized Claim"
                           shall be $0 since the artificial inflation on the
                           date of purchase was the same as the artificial
                           inflation on the date of sale, meaning that any
                           decline in the value of the option was attributable
                           to something other than the alleged fraud.

                  e.       No Recognized Claim shall be allowed with respect to
                           call option(s) which were purchased and then expired
                           during the Class Period..

         5. PUT OPTIONS

                  a.       With respect to PUT OPTIONS TO SELL SHARES OF
                           PEDIATRIX COMMON STOCK sold during the Class Period,
                           an Authorized Claimant's "Recognized Claim" shall
                           mean the amount determined in accordance with the
                           following: for each Put Option on Pediatrix common
                           stock sold on the open market

--------------------

4 The Recognized Claim for Call Options is discounted to reflect the fact that
part of the purchase price paid for a Call Option is a time premium which is a
wasting asset which is essentially unrelated to the alleged inflation.

                                       10
<PAGE>

                           during the Class Period WHICH REMAINED AS AN OPEN AND
                           UNEXPIRED OPTION AS OF APRIL 2, 1999 (the end of the
                           Class Period), the Recognized Claim shall be equal to
                           50%5 of the amount, if any, that the Put Option was
                           "in the money" as of the close of trading on April 5,
                           1999 (the first day of trading after the end of the
                           Class Period), less the price received (excluding
                           commissions, etc.) for the Put Option(s) times the
                           number of shares covered by such Put Option(s).

                  b.       If a Put Option was assigned during the Class Period
                           and shares of Pediatrix common stock were purchased,
                           the Recognized Claim from such a transaction shall be
                           calculated as a purchase of Pediatrix common stock
                           and the Authorized Claimant will have no "Recognized
                           Claim" with respect to the sale of the option. The
                           date of the assignment of the Put Option is the
                           "Purchase" date.

                  c.       No Recognized Claim shall be allowed with respect to
                           Put Option(s) sold or written during the Class Period
                           to cover Put Option(s) previously purchased by a
                           claimant.

                  d.       With respect to Put Option(s) sold and then covered
                           during the Class Period, the "Recognized Claim" shall
                           be $0 since the artificial inflation on the date of
                           the sale was the same as the artificial inflation on
                           the date of the cover, meaning that any decline in
                           the value of the option was attributable to something
                           other than the alleged fraud.

                  e.       No Recognized Claim shall be allowed with respect to
                           Put Option(s) which were sold and then expired during
                           the Class Period.

         6. Note that $10.34 is the consistent amount of inflation calculated by
Plaintiffs' counsel's expert for Pediatrix common stock during the Class Period.
Neither $10.34 nor the Recognized Claim amount described herein is the amount
you will recover. The Recognized Claim is an amount that is used in determining
the pro-rata amount of the Settlement Fund you will recover. YOUR ACTUAL
RECOVERY WILL BE LESS THAN YOUR RECOGNIZED CLAIM, AND YOUR ACTUAL RECOVERY WILL
BE LESS THAN $10.34 PER SHARE.

         7. In determining Recognized Claims, brokerage commissions and all
other transaction costs shall be excluded from the calculation. Transactions
resulting in a gain shall not be included. With respect to Class Members who had
multiple purchases of Pediatrix common stock, Recognized Claims shall be
determined using the first-in-first-out basis, beginning with shares held as of
March 30, 1997.

         8. Pediatrix common stock or call options acquired during the Class
Period by means of a gift, inheritance or operation of law, are not eligible to
share in the Net Settlement

-------------------

5 The Recognized Claim for Put Options is discounted to reflect the fact that
part of the sale price received for a Put Option is a time premium which is a
wasting asset that is essentially unrelated to the alleged inflation.

                                       11
<PAGE>

Fund based on such acquisition unless the transferor or donor on such a
transaction would have been entitled to share in the Net Settlement Fund based
on his, her or its acquisition. If the transferor or donor submits a claim
relating to his, her or its acquisition of such shares or options, then any
claim submitted by the transferee or donee with respect to such shares or
options will be rejected.

VI. THE RIGHTS OF CLASS MEMBERS

         The Court has previously certified this Action to proceed as a class
action. Class members have the following rights pursuant to Rule 23(c)(2) of the
Federal Rules of Civil Procedure:

                  (a) Class members may share in the proceeds of the Settlement,
provided that you submit an acceptable Proof of Claim, as outlined in Section
VII below.

                  (b) Class members will be represented by the Lead Plaintiffs
and their counsel, unless you enter an appearance through counsel of your own
choice at your own expense. You are not required to retain your own counsel, but
if you do chose to do so, such counsel must file an appearance on your behalf on
or before [14 days prior to the Settlement Hearing] _________________, 2002, and
must serve copies of such an appearance on the attorneys listed in Section XI of
this Notice.

                  (c) Class members may object to the Settlement, the Plan of
Allocation or the attorneys' fees and/or expense application. Any Class member
may appear in person or by counsel and be heard to the extent allowed by the
Court in opposition to the fairness, reasonableness and adequacy of the
Settlement, the Plan of Allocation or the application for an award of attorneys'
fees and reimbursement of expenses, by following the procedures outlined in
Section IX below.

                  (d) Any Class member wishing to preserve appellate rights with
respect to any portion of the Settlement, the Plan of Allocation or application
for an award of attorneys' fees and reimbursement of expenses must timely
intervene as a party plaintiff pursuant to Rule 24 of the Federal Rules of Civil
Procedure to preserve such rights of appeal.

VII. FILING AND PROCESSING OF PROOFS OF CLAIM

         IN ORDER TO BE ELIGIBLE TO RECEIVE ANY DISTRIBUTION FROM THE SETTLEMENT
FUND, YOU MUST COMPLETE AND SIGN THE ATTACHED PROOF OF CLAIM AND RELEASE FORM
AND SEND IT BY PRE-PAID FIRST CLASS MAIL POST-MARKED ON OR BEFORE _____________,
2002, ADDRESSED AS FOLLOWS:

                              Claims Administrator
                    Pediatrix Medical Group, Inc. Sec. Litig.
                         c/o The Garden City Group, Inc.
                                  P.O. Box 9269
                        Garden City, New York 11530-9269

                                       12
<PAGE>

         IF YOU DO NOT FILE A PROPER PROOF OF CLAIM FORM, YOU WILL NOT BE
ENTITLED TO ANY SHARE OF THE SETTLEMENT FUND.

         IF YOU ARE A CLASS MEMBER, YOU WILL BE BOUND BY THE SETTLEMENT AND
ORDER AND FINAL JUDGMENT OF THE COURT DISMISSING THIS LITIGATION, EVEN IF YOU DO
NOT FILE A PROOF OF CLAIM.

         All Proofs of Claim must be submitted by the date specified by this
Notice unless such period is extended by Order of the Court.

         Each Claimant shall be deemed to have submitted to the jurisdiction of
the United States District Court for the Southern District of Florida with
respect to his, her or its claim.

VIII. EXCLUSION FROM THE SETTLEMENT

         Notice of the pendency of this Action as a class action was given to
the members of the Class in June and July, 2001. Class members were notified of
their right to exclude themselves by filing a request for exclusion postmarked
on or before August 27, 2001. Persons and entities who filed requests for
exclusion may not share in this Settlement. Class members may no longer request
exclusion at this time.

IX. SETTLEMENT HEARING

         At the Settlement Hearing, the Court will determine whether to finally
approve this Settlement and Plan of Allocation and dismiss the Action and the
claims of the Class. The Settlement Hearing may be adjourned from time-to-time
by the Court without further written notice to the Class.

         At the Settlement Hearing, any Class member who has not properly filed
a request for exclusion from the Class may appear in person or by counsel and be
heard to the extent allowed by the Court in opposition to the fairness,
reasonableness and adequacy of the Settlement, the Plan of Allocation, or the
application for an award of attorneys' fees and reimbursement of expenses,
provided, however, that in no event shall any person be heard in opposition to
the Settlement, Plan of Allocation, and, or counsels' application for an award
of attorneys' fees and reimbursement of expenses and in no event shall any paper
or brief submitted by any such person be accepted or considered by the Court,
unless, on or before [14 days prior to the Settlement Hearing] such person (a)
files with the Clerk of Court notice of such person's intention to appear,
together with a statement that indicates the basis for such opposition, along
with any documentation in support of such objection, and (b) simultaneously
serves copies of such notice, statement and documentation, together with copies
of any other papers or briefs such person files with the Court, including the
identity of any witnesses to be called and any exhibits to be offered in
evidence, in person or by mail upon Plaintiffs' Co-Lead Counsel:

                                       13
<PAGE>

         Michael J. Pucillo, Esq.                    John P. Coffey, Esq.
         Wendy H. Zoberman, Esq.                     Rochelle Feder Hansen, Esq.
         Berman DeValerio Pease                      Bernstein Litowitz Berger
           Tabacco Burt & Pucillo                      & Grossmann LLP
         515 N. Flagler Dr., Ste. 1701               1285 Avenue of the Americas
         West Palm Beach, FL 33401                   New York, NY 10019

and upon Defendants' counsel:

         Barry Rodney Davidson, Esq.                 Robert F. Wise, Jr., Esq.
         Hunton & Williams                           Davis Polk & Wardwell
         1111 Brickell Avenue                        450 Lexington Avenue
         Suite 2500                                  New York, NY 10017
         Miami, FL 33131-3136

         Unless otherwise ordered by the Court, any Class Member who does not
make his, her or its objection or opposition in the manner provided shall be
deemed to have waived such objection.

X. NOTICE TO BANKS, BROKERS OR OTHER NOMINEES

         A. If you purchased Pediatrix common stock or call options or sold
Pediatrix put options during the Class Period as a nominee for the benefit of
another, or were or are holding certificates of Pediatrix stock in your name as
nominee for someone who purchased Pediatrix stock during the Class Period, you
are directed within 10 business days from receipt of this Notice to either: (a)
provide the names and addresses of such persons to the Claims Administrator, c/o
Pediatrix Medical Group, Inc. Sec. Litig., The Garden City Group, Inc., P.O. Box
9269, Garden City, New York 11530-9269, Telephone: 1-888-212-5795, in which case
the beneficial owner will be sent a copy of the Notice and Proof of Claim Form;
or (b) request additional copies of this Notice, which will be provided to you
free of charge, and within seven (7) days of receipt of those copies mail the
Notice and Proof of Claim Form to the beneficial owners of the securities
referred to herein. You may receive reimbursement for your reasonable and actual
out-of-pocket disbursements that would not have been made but for this request
upon submission of an itemized statement to the Claims Administrator. If you
choose to follow alternative procedure (b), the Court has ordered that you must,
upon such mailing, send a statement to the Claims Administrator confirming that
the mailing was made as directed.

XI. FURTHER INFORMATION

         A. The pleadings and other records of the Class Action, may be examined
and copied at any time during regular office hours at the Office of the Clerk,
United States District Court, Southern District of Florida, 299 East Broward
Blvd., Ft. Lauderdale, FL 33301.

         B. ALL INQUIRIES CONCERNING THIS NOTICE OR THE PROOF OF CLAIM FORM BY
CLASS MEMBERS SHOULD BE MADE TO THE CLAIMS ADMINISTRATOR IN WRITING AT THE
ADDRESS LISTED ABOVE OR BY CALLING 1-888-212-5795.

                                       14
<PAGE>

DO NOT CALL OR WRITE THE COURT OR THE OFFICE OF THE CLERK OF THE COURT FOR
INFORMATION OR ADVICE.

Dated:  ___________, 2002                     Clerk of the Court
                                              United States District Court
                                              Southern District of Florida

                                       15
<PAGE>

                                                                       EXHIBIT 2

                          UNITED STATES DISTRICT COURT
                          SOUTHERN DISTRICT OF FLORIDA

                          CASE NO. 99-6181-CIV-GONZALEZ

SANDS POINT PARTNERS, L.P.,
et al. on behalf of themselves and
all others similarly situated,

                  Plaintiffs,

vs.

PEDIATRIX MEDICAL GROUP, INC.,
ROGER J. MEDEL, KARL B. WAGNER,
and LAWRENCE M. MULLEN,

                  Defendants.

                                  /
----------------------------------

                           PROOF OF CLAIM AND RELEASE

DEADLINE FOR SUBMISSION:  ___________________, 2002.

INSTRUCTIONS FOR FILING PROOF OF CLAIM

         In order for you to qualify to participate in the distribution
described in the Notice of Pro-posed Settlement of Class Action, Settlement
Fairness Hearing and Right to Share in Settlement Fund (the "Notice"), you must
execute and file a Proof of Claim and Release in the form attached hereto and
you must provide the required documentation to substantiate your claim. If you
fail to timely file a properly addressed (as set forth in P. 4 below) Proof of
Claim and Release, your claim may be rejected and you may be precluded from any
recovery from the Net Settlement Fund created in connection with the proposed
settlement of this class action.

<PAGE>

                             REQUIREMENTS FOR FILING

         Your claim will be considered only upon compliance with all of the
following conditions:

1. You must accurately complete all portions of the attached Proof of Claim
form.

NOTE: The Proof of Claim contains purchase and sale schedules for Pediatrix
Medical Group, Inc.'s common stock, and call options and put options on the
stock. You must carefully complete these schedules. Do not omit to state any
potentially relevant information regarding your purchases and sales of Pediatrix
common stock or call options or put options. This information is necessary to
determine your share of any distributions. If you cannot list all transactions
in the spaces provided in the Proof of Claim form, or if you believe that you
must or should supply additional information with respect to any transaction,
attach additional sheets to the Proof of Claim supplying the required
information. You must be properly identified on each additional sheet of paper.
The date of purchase and sale is the "trade" or "contract" date, and not the
"settlement" or "payment" date. The purchase price is the price paid excluding
commissions or other expenses. The sales price is price received less
commissions or other expenses.

2. You must SIGN the Proof of Claim form.

NOTE: If the securities were or are owned jointly, all joint owners must sign
the Proof of Claim. Executors, administrators, guardians, conservators and
trustees may complete and sign the Proof of Claim on behalf of persons or
entities represented by them, but they must identify such persons or entities
and provide proof of their authority (for example, currently effective letters
testamentary or letter of administration) to complete and execute the Proof of
Claim. Any Proof of Claim submitted by legal representatives of a claimant must
be executed by all such representatives.

3. You must attach to the Proof of Claim form legible copies of broker
confirmation slips, monthly brokerage statements or other satisfactory proof
confirming your opening balance in

                                       2
<PAGE>

Pediatrix common stock and/or call options and/or put options as of March 31,
1997 (the first day of the Class Period) as well as the particulars of each
purchase and sale you made of Pediatrix common stock and/or call options and/or
put options between March 31,1997 through and including April 2, 1999. IF ANY
SUCH DOCUMENTS ARE NOT IN YOUR POSSESSION, PLEASE OBTAIN A COPY OR EQUIVALENT
DOCUMENTS FROM YOUR BROKER OR TAX ADVISOR BECAUSE THESE DOCUMENTS ARE NECESSARY
TO PROVE AND PROCESS YOUR CLAIM.

4. You must mail the completed and signed Proof of Claim and supporting
documents by first-class mail, postage prepaid, postmarked no later than ,
_____________________, 2002 to:

                              Claims Administrator
               Pediatrix Medical Group, Inc. Securities Litigation
                         c/o The Garden City Group, Inc.
                                  P.O. Box 9269
                        Garden City, New York 11530-9269
                            Telephone: (888) 212-5795

         Your failure to complete and mail the Proof of Claim by that date may
preclude you from receiving any share of the available distributions. So that
you will have a record of the date of your mailing and its receipt by the Claims
Administrator, you are advised to use certified mail, return receipt requested.
PLEASE KEEP A COPY OF ALL DOCUMENTS THAT YOU SEND TO THE CLAIMS ADMINISTRATOR.

                                       3
<PAGE>
                               REMINDER CHECKLIST:

1.       Please sign the verification and certification section of the Proof of
         Claim form.

2.       Remember to attach supporting documentation.

3.       Do not send original stock certificates.

4.       Keep a copy of your claim form and all supporting documentation for
         your records.

5.       If you desire an acknowledgment of receipt of your claim form, please
         send it Certified Mail, Return Receipt Requested.

6.       If you move, please promptly send the Claims Administrator your new
         address:

ANY PERSON WHO KNOWINGLY SUBMITS A FALSE PROOF OF CLAIM IS SUBJECT TO PENALTIES
FOR PERJURY AND OTHER VIOLATIONS OF FEDERAL LAW

                                       4
<PAGE>
                              Claims Administrator
              Pediatrix Medical Group, Inc. Securities Litigation
                        c/o The Garden City Group, Inc.
                                 P.O. Box 9269
                        Garden City, New York 11530-9269
                           Telephone: (888) 212-5795

MUST BE POSTMARKED NO LATER THAN

________________________________ , 2002

CLASS MEMBER MUST COMPLETE AND TIMELY SUBMIT THIS FORM IN ORDER TO BE ELIGIBLE
TO PARTICIPATE IN ANY DISTRIBUTION OF THE NET SETTLEMENT FUND.

                                 PROOF OF CLAIM
                             (Please Print or Type)

I.       IDENTITY OF CLAIMANT

     (Complete only the applicable portions)

      __Individual          __Partnership        __Corporation

      __Estate              __Trust              __Two or more persons as joint
                                                   owners

       __IRA, Keogh or Other Type of Individual Retirement Plan _______Agent or
       Attorney (indicate type of plan, mailing address, and name of current
       custodian)

       __Other (Describe on separate sheet).

(Fill in only those of the following that are applicable to you)

A.       Name or Legal Name of Claimant:
                                         ---------------------------------------
         Mailing Address:
                          ------------------------------------------------------
         Telephone No.:   Day                       Evening
                              --------------------         ---------------------

B.       Legal Representative:
                               -------------------------------------------------
         Mailing Address:
                               -------------------------------------------------
         Telephone No.:   Day                       Evening
                              ---------------------         --------------------

                                       1
<PAGE>

(LEGAL REPRESENTATIVE OF CLAIMANTS MUST ATTACH POWER OF ATTORNEY OR THE
INSTRUMENT SHOWING AUTHORITY TO ACT AS AGENT.)

         1. By submitting this Proof of Claim, I state that I believe in good
faith that I am a Class Member as defined above and in the Notice of Proposed
Settlement, Settlement Hearing And Right To Share In Settlement Fund (the
"Notice"), or am acting for such person; that I am not a Defendant in the action
or anyone excluded from the Class; that I have read and understand the Notice;
that I believe that I am entitled to receive a share of the Net Settlement Fund;
that I elect to participate in the proposed Settlement described in the Notice;
and that I have not filed a request for exclusion.

         2. I have set forth where requested below all relevant information with
respect to each purchase and/or sale of Pediatrix Medical Group, Inc. Common
Stock and/or Call Options and/or put options on Pediatrix Medical Group, Inc.
Common Stock, during the Class Period.

         3. I have enclosed photocopies of the stockbroker's confirmation slips,
stockbroker's statements or other documents evidencing each purchase and each
sale or retention of Pediatrix Medical Group, Inc. Common Stock and/or Call
Options and/or put options on Pediatrix Medical Group, Inc. Common Stock, listed
below in support of my claim.

         4. I understand that the information contained in this Proof of Claim
is subject to such verification as the Court may direct, and I agree to
cooperate in any such verification. I further agree and understand that if the
proposed Settlement is approved by the Court and becomes effective, all claims,
demands, or causes of action against any or all Defendants, and certain other
persons or entities further identified below, which have been or could have been
asserted relating to the subject matter of the Action will be satisfied,
discharged and extinguished forever.

                                       2
<PAGE>

         5. Upon the occurrence of the Effective Date (as defined in the Notice)
my signature hereto will constitute a full and complete release, remise and
discharge by me or, if I am submitting this Proof of Claim on behalf of a
corporation, a partnership, estate or one or more other per-sons, by it, him,
her or them, and by my, its, his, her or their heirs, executors, administrators,
successors, and assigns, of each of the "Released Parties" of all "Released and
Settled Claims," as defined in the Notice.

II. TRANSACTIONS IN PEDIATRIX COMMON STOCK

SECTION B:     BEGINNING HOLDINGS: Number of shares of Common Stock of
               Pediatrix Medical Group, Inc. owned as of the close of trading on
               March 30, 1997:

SECTION P:     PURCHASES: of Pediatrix Medical Group, Inc. Common Stock
               between March 31, 1997 and April 2, 1999, inclusive. Except as
               described in Section V, paragraph ____ of the Notice, persons who
               received Pediatrix common stock during the Class Period other
               than by purchase -- e.g. by gift or inheritance -- are not
               entitled to file claims for those transactions:

<TABLE>
<CAPTION>

  Trade Date(s) of
 Purchase (Exercise                                                             Complete only if purchase was result
 or Assignment Date                                                               of option exercise or assignment.
 if obtained due to                                           Aggregate Cost     ------------------------------------
     an option        Number of Shares     Purchase Price       (excluding         Enter "E" if
 transaction) (List    of Common Stock      Per Share of        commission,      Exercised or "A"    Premium Paid or
  Chronologically)        Purchased         Common Stock      taxes and fees)      if Assigned          Received
 ------------------   ----------------     --------------     ---------------    ----------------    ---------------
<S>                   <C>                <C>                 <C>                 <C>                 <C>
                                         $                   $

 ------------------   ----------------     --------------     ---------------    ----------------    ---------------
                                         $                   $

 ------------------   ----------------     --------------     ---------------    ----------------    ---------------
                                         $                   $

 ------------------   ----------------     --------------     ---------------    ----------------    ---------------
                                         $                   $

 ------------------   ----------------     --------------     ---------------    ----------------    ---------------
                                         $                   $

 ------------------   ----------------     --------------     ---------------    ----------------    ---------------
                                         $                   $

 ------------------   ----------------     --------------     ---------------    ----------------    ---------------

</TABLE>

                                       3
<PAGE>

SECTION S:     SALES: of Pediatrix Medical Group, Inc. Common Stock between
               March 31, 1997 and April 2, 1999, inclusive. (Please list in
               chronological order.)

<TABLE>
<CAPTION>

                                                                                Complete only if purchase was result
                                                                                  of option exercise or assignment.
 Trade Date(s) of                                             Total Proceeds     ------------------------------------
    Sale (List        Number of Shares       Sale Price         (excluding         Enter "E" if
 Chronologically)      of Common Stock      Per Share of        commission,      Exercised or "A"    Premium Paid or
 Month/Day/Year             Sold            Common Stock      taxes and fees)      if Assigned          Received
 ------------------   ----------------     --------------     ---------------    ----------------    ---------------
<S>                   <C>                <C>                 <C>                 <C>                 <C>
                                         $                   $

 ------------------   ----------------     --------------     ---------------    ----------------    ---------------
                                         $                   $

 ------------------   ----------------     --------------     ---------------    ----------------    ---------------
                                         $                   $

 ------------------   ----------------     --------------     ---------------    ----------------    ---------------
                                         $                   $

 ------------------   ----------------     --------------     ---------------    ----------------    ---------------
                                         $                   $

 ------------------   ----------------     --------------     ---------------    ----------------    ---------------
                                         $                   $

 ------------------   ----------------     --------------     ---------------    ----------------    ---------------

</TABLE>

SECTION U:     UNSOLD: Number of shares of Pediatrix Medical Group, Inc.
               Common Stock owned as of April 2, 1999:

III. TRANSACTIONS IN CALL OPTIONS ON PEDIATRIX COMMON STOCK.

SECTION B:     BEGINNING POSITION: Number of Contracts of Call Options1 for
               Pediatrix Medical Group, Inc. Common Stock owned as of the close
               of trading on March 30, 1997, in a short or long position:

<TABLE>
<CAPTION>

        Number of Call             Month and Strike Price of     Total Amount Paid for Call
       Option Contracts             Options (i.e., Aug 20)       Option (ONLY if exercised)
       ----------------            -------------------------     --------------------------

       <S>                        <C>                            <C>
       ----------------            -------------------------     --------------------------

       ----------------            -------------------------     --------------------------

       ----------------            -------------------------     --------------------------

</TABLE>

-----------------------

1 Each Call Option contract covers 100 shares of Pediatrix Common Stock.

                                       4
<PAGE>

SECTION P:     PURCHASES: of Call Options for Pediatrix Medical Group, Inc.
               Common Stock between March 31, 1997 and April 2, 1999, inclusive.
               (Please list in chronological order.)

<TABLE>
<CAPTION>

                                                            Total Amount Paid
                                                             for Call Option
  Trade Date(s) of       Number of         Month and          (excluding           Enter "E"            Exercised
   Purchase (List       Call Option       Strike Price     commissions, taxes    Exercised or "X"         Date
  Chronologically)       Contracts       (i.e., Aug 20)   and fees, omit cents)     if expired          mm/dd/yy
<S>                     <C>              <C>              <C>                    <C>                   <C>
--------------------- ----------------- ----------------- ---------------------- ------------------ ------------------
                                                          $

--------------------- ----------------- ----------------- ---------------------- ------------------ ------------------
                                                          $
--------------------- ----------------- ----------------- ---------------------- ------------------ ------------------
                                                          $
--------------------- ----------------- ----------------- ---------------------- ------------------ ------------------
</TABLE>

SECTION S:     SALES:  of Call Options for Pediatrix Medical Group, Inc. Common
               Stock between March 31, 1997 and April 2, 1999, inclusive.
               (Please list in chronological order.)

<TABLE>
<CAPTION>

                                                            Total Amount Paid
                                                             for Call Option
  Trade Date(s) of       Number of         Month and          (excluding           Enter "E"            Exercised
   Purchase (List       Call Option       Strike Price     commissions, taxes    Exercised or "X"         Date
  Chronologically)       Contracts       (i.e., Aug 20)   and fees, omit cents)     if expired          mm/dd/yy
<S>                     <C>              <C>              <C>                    <C>                   <C>
--------------------- ----------------- ----------------- ---------------------- ------------------ ------------------
                                                          $

--------------------- ----------------- ----------------- ---------------------- ------------------ ------------------
                                                          $
--------------------- ----------------- ----------------- ---------------------- ------------------ ------------------
                                                          $
--------------------- ----------------- ----------------- ---------------------- ------------------ ------------------
</TABLE>

SECTION U:     UNSOLD: Number of contracts of Call Options for Pediatrix
               Medical Group, Inc. Common Stock held as of April 2, 1999 in a
               short or long position:

                                           Month and Strike Price
           Number of Call                        of Options
          Option Contracts                     (i.e., Aug 20)
          ----------------                 ----------------------

          ----------------                 ----------------------

          ----------------                 ----------------------

          ----------------                 ----------------------

                                       5
<PAGE>

IV. TRANSACTIONS IN PUT OPTIONS ON PEDIATRIX'S COMMON STOCK

SECTION B:     BEGINNING HOLDINGS: Number of Contracts of Put Options2 for
               Pediatrix Medical Group, Inc. Common Stock owned as of the close
               of trading on March 30, 1997, in a short or long position:

<TABLE>
<CAPTION>

       Number of Put               Month and Strike Price of                 Total Amount Paid for
     Option Contracts                Options (i.e., Aug 20)             Put Option (ONLY if exercised)
     <S>                          <C>                                   <C>

     ----------------              -------------------------            ------------------------------

     ----------------              -------------------------            ------------------------------

     ----------------              -------------------------            ------------------------------

     ----------------              -------------------------            ------------------------------

</TABLE>

SECTION S:     SALES: of Put Options for Pediatrix Medical Group, Inc. Common
               Stock between March 31, 1997 and April 2, 1999, inclusive.
               (Please list in chronological order.)

<TABLE>
<CAPTION>

                                                            Total Amount Paid
                                                             for Call Option
  Trade Date(s) of       Number of         Month and          (excluding           Enter "E"            Exercised
   Purchase (List       Call Option       Strike Price     commissions, taxes    Exercised or "X"         Date
  Chronologically)       Contracts       (i.e., Aug 20)   and fees, omit cents)     if expired          mm/dd/yy
<S>                     <C>              <C>              <C>                    <C>                   <C>
--------------------- ----------------- ----------------- ---------------------- ------------------ ------------------
                                                          $

--------------------- ----------------- ----------------- ---------------------- ------------------ ------------------
                                                          $
--------------------- ----------------- ----------------- ---------------------- ------------------ ------------------
                                                          $
--------------------- ----------------- ----------------- ---------------------- ------------------ ------------------
</TABLE>

--------------------

2 Each Call Option contract covers 100 shares of Pediatrix Common Stock.

                                       6
<PAGE>

SECTION P:     PURCHASES: of Put Options for Pediatrix Medical Group, Inc.
               Common Stock between March 31, 1997 and April 2, 1999, inclusive.
               (Please list in chronological order.)

<TABLE>
<CAPTION>

                                                            Total Amount Paid
                                                             for Call Option
  Trade Date(s) of       Number of         Month and          (excluding           Enter "E"            Exercised
   Purchase (List       Call Option       Strike Price     commissions, taxes    Exercised or "X"         Date
  Chronologically)       Contracts       (i.e., Aug 20)   and fees, omit cents)     if expired          mm/dd/yy
<S>                     <C>              <C>              <C>                    <C>                   <C>
--------------------- ----------------- ----------------- ---------------------- ------------------ ------------------
                                                          $

--------------------- ----------------- ----------------- ---------------------- ------------------ ------------------
                                                          $
--------------------- ----------------- ----------------- ---------------------- ------------------ ------------------
                                                          $
--------------------- ----------------- ----------------- ---------------------- ------------------ ------------------
</TABLE>

SECTION U:    UNSOLD: Number of contracts of Put Options for Pediatrix
               Medical Group, Inc. Common Stock held as of April 2, 1999 in a
               short or long position:

                                           Month and Strike Price
           Number of Put                         of Options
          Option Contracts                     (i.e., Aug 20)
          ----------------                 -----------------------

          ----------------                 -----------------------

          ----------------                 -----------------------

          ----------------                 -----------------------

V. SUBSTITUTE FORM W-9

         Request for Taxpayer Identification Number:

         Enter taxpayer identification number below for the Beneficial Owner(s).
For most individuals, this is your Social Security number. The Internal Revenue
Service ("I.R.S.") requires such taxpayer identification number. If you fail to
provide this information, your claim may be rejected.

                                             Social Security Number
-------------------------------------------
(for individuals) or

                                             Employer Identification Number
-------------------------------------------
(for estates, trusts, corporations, etc.)

                                       7
<PAGE>

VI. CERTIFICATION

         UNDER THE PENALTIES OF PERJURY, I (WE) CERTIFY THAT ALL OF THE
INFORMATION PROVIDED ON THIS FORM IS TRUE, CORRECT AND COMPLETE

         I (We) certify that I am (we are) NOT subject to backup withholding
under the provisions of Section 3406 (a)(1)(c) of the Internal Revenue Code
because: (a) I am (We are) exempt from backup withholding, or (b) I (We) have
not been notified by the I.R.S. that I am (we are) subject to backup withholding
as a result of a failure to report all interest or dividends, or (c) the I.R.S.
has notified me (us) that I am (we are) no longer subject to backup withholding.

NOTE: If you have been notified by the I.R.S. that you are subject to backup
withholding, please strike out the language that you are not subject to backup
withholding in the certification above.

SIGNATURE OF CLAIMANT(S):
(if this claim is being made on behalf of Joint Claimants, then each must sign.)

--------------------------------------    -------------------------------------
             (Signature)                               (Signature)

Date:
       -----------------------------

                                       8
<PAGE>
                                    EXHIBIT 3

                          UNITED STATES DISTRICT COURT
                          SOUTHERN DISTRICT OF FLORIDA

                          CASE NO. 99-6181-CIV-GONZALEZ

SANDS POINT PARTNERS, L.P., et al., on behalf of themselves and
all others similarly situated,

                                    Plaintiffs,

                  -against-

PEDIATRIX MEDICAL GROUP, INC., ROGER J. MEDEL, KARL B. WAGNER
and LAWRENCE M. MULLEN

                  Defendants.
                                     /
------------------------------------

                      SUMMARY NOTICE OF PROPOSED SETTLEMENT
                             AND SETTLEMENT HEARING

TO:      ALL PERSONS AND ENTITIES ("THE CLASS") WHO PURCHASED COMMON STOCK OR
         CALL OPTIONS, OR SOLD PUT OPTIONS OF PEDIATRIX MEDICAL GROUP, INC.
         BETWEEN MARCH 31, 1997 AND APRIL 2, 1999, INCLUSIVE (THE "CLASS
         PERIOD")

         YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of
Civil Procedure and an order of the United States District Court for the
Southern District of Florida, dated ________________, 2002, that a hearing will
be held on ________________, 2002, at __________, before the Honorable Jose A.
Gonzalez, Jr., at the United States Courthouse, 299 East Broward Blvd., Fort
Lauderdale, Florida 33301, for the purpose of determining: (i) whether the
proposed settlement of the above Action for the principal amount of Twelve
Million Dollars ($12,000,000) cash, plus accrued interest, should be approved by
the Court as fair, reasonable and adequate; (ii) whether an Order and Final
Judgment approving the Settlement and dismissing

<PAGE>

this Action on the merits and with prejudice should be entered; and (iii)
whether the application of Plaintiffs' counsel for the payment of attorneys'
fees and expenses are reasonable and should be approved.

         IF YOU ARE A MEMBER OF THE CLASS DESCRIBED ABOVE, YOUR RIGHTS WILL BE
AFFECTED AND YOU MAY BE ENTITLED TO SHARE IN THE SETTLEMENT FUND. If you have
not yet received the full printed Notice of Proposed Settlement of Class Action,
Settlement Fairness Hearing, and Right to Share in Settlement Fund and a Proof
of Claim form, you may obtain copies of these documents by identifying yourself
as a member of the Class and writing to:

                              Claims Administrator
               Pediatrix Medical Group, Inc. Securities Litigation
                         c/o The Garden City Group, Inc.
                                  P.O. Box 9269
                        Garden City, New York 11530-9269
                            Telephone: (888) 212-5795

         All inquiries other than requests for the forms of Notice and Proof of
Claim, should be made in writing, addressed to Plaintiffs' Co-Lead Counsel:

Michael J. Pucillo, Esq.                           John P. Coffey, Esq.
Wendy H. Zoberman, Esq.                            Rochelle Feder Hansen, Esq.
Berman DeValerio Pease                             Bernstein Litowitz Berger
Tabacco Burt & Pucillo                             & Grossmann LLP
515 N. Flagler Dr., Suite 1701                     1285 Avenue of the Americas
West Palm Beach, FL  33401                         New York, NY 10019
(561) 835-9400                                     (212) 554-1400

         To participate in the Settlement, you must file a Proof of Claim no
later than _______________, 2002. IF YOU ARE A CLASS MEMBER AND DO NOT FILE A
PROPER, TIMELY PROOF OF CLAIM, YOU WILL NOT SHARE IN THE SETTLEMENT BUT YOU WILL
BE BOUND BY THE FINAL ORDER AND JUDGMENT OF THE COURT.

                                       2
<PAGE>

PLEASE DO NOT CALL OR WRITE THE COURT OR THE OFFICE OF THE CLERK OF THE COURT
FOR INFORMATION OR ADVICE.

Dated:  _______________                          BY ORDER OF THE
                                                 United States District Court
                                                 Southern District of Florida

                                       3
<PAGE>

                                    EXHIBIT B

                          UNITED STATES DISTRICT COURT
                          SOUTHERN DISTRICT OF FLORIDA

                          CASE NO. 99-6181-CIV-GONZALEZ

SANDS POINT PARTNERS, L.P.,
et al. on behalf of themselves and
all others similarly situated,

                  Plaintiffs,

vs.

PEDTATRIX MEDICAL GROUP, INC.,
ROGER J. MEDEL, KARL B. WAGNER,
and LAWRENCE M. MULLEN,

                  Defendants.

                                     /
-------------------------------------

                            ORDER AND FINAL JUDGMENT

         On this _____ day of ________________, 2002, a hearing having been held
before this Court to determine: (1) whether the terms and conditions of the
Stipulation and Agreement of Settlement, dated as of ________________, 2002 (the
"Stipulation") are fair, adequate and reasonable for the settlement of all
claims asserted by the Class against the Defendants in the Complaint now pending
in this Court under the above caption, including the release of the Defendants
and the Released Parties and should be approved; (2) whether judgment should be
entered dismissing the Complaint on the merits and with prejudice in favor of
the Defendants as against all persons or entities who are members of the Class
herein who have not requested exclusion therefrom; (3) whether to approve the
Plan of Allocation as a fair and reasonable method to allocate the settlement
proceeds among the members of the Class; and (4) whether and in what amount to
award counsel for Plaintiffs and the Class fees and reimbursement of

<PAGE>

expenses. On November 6, 2000, this Court, pursuant to Rules 23(a) and (b)(3)
certified a class consisting of: All persons who purchased Pediatrix Medical
Group, Inc. ("Pediatrix") common stock, purchased Pediatrix call options, or
sold Pediatrix put options between March 31, 1997 and April 2, 1999, inclusive
(the "Class Period"). Excluded from the Class are Pediatrix, its subsidiaries
and affiliates, the Individual Defendants, members of the immediate families of
each of the Individual Defendants, and any entities in which any of the
Defendants has a controlling interest, and the legal representatives, heirs,
successors, affiliates or assigns of any of the foregoing excluded persons and
entities. Also excluded from the Class are the persons and/or entities who
requested exclusion from the Class as listed on Exhibit A annexed hereto. The
Court having considered all matters submitted to it at the hearing and
otherwise; and it appearing that a Notice of the hearing substantially in the
form approved by the Court was mailed to all persons or entities reasonably
identifiable, who purchased common stock or call options or sold put options of
Pediatrix Medical Group, Inc., during, the Class Period, except those persons or
entities excluded from the definition of the Class, and that a Publication
Notice of the hearing substantially in the form approved by the Court was
published over the BUSINESS WIRE and in INVESTORS BUSINESS DAILY pursuant to the
specifications of the Court; and the Court having considered and determined the
fairness and reasonableness of the award of attorneys' fees and expenses
requested; and all capitalized terms used herein having the meanings as set
forth and defined in the Stipulation.

         NOW, THEREFORE, IT IS HEREBY ORDERED THAT:

         1. The Court has jurisdiction over the subject matter of the Action,
the Lead Plaintiffs, all other Class Members and the Defendants.

                                       2
<PAGE>

         2. Pursuant to and in accordance with the requirements of Rule 23, the
Settlement as set forth in the Stipulation is approved as fair, reasonable and
adequate, and in the best interests of the Class, and the Class Members and the
parties are directed to consummate the Stipulation in accordance with its terms
and provisions.

         3. The distribution of the Notice of Proposed Settlement of Class
Action, Settlement Fairness Hearing, and Right to Share in Settlement Fund, and
publication of the Summary Notice of Proposed Settlement and Settlement Hearing
as provided in the Preliminary Order in Connection with Settlement Proceedings
constituted the best notice practicable under the circumstances to all Class
Members, and fully met the requirements of Rule 23 of the Federal Rules of Civil
Procedure, due process, the United States Constitution, and any other applicable
law.

         4. The Complaint is hereby dismissed with prejudice and without costs,
except as provided in the Stipulation, as against Pediatrix, the Individual
Defendants, their past or present subsidiaries, parents, affiliates, partners,
successors and predecessors, officers, directors, shareholders, insurers,
reinsurers, agents, employees, attorneys, advisors, and investment advisors,
auditors, accountants and any person, firm, trust, corporation, officer,
director or other individual or entity in which any Defendant has a controlling
interest or which is related to or affiliated with any of the Defendants, and
the legal representatives, heirs, successors in interest or assigns of the
Defendants.

         5. Lead Plaintiffs and the other Members of the Class and the
successors and assigns of any of them, are hereby permanently barred and
enjoined from instituting, commencing or prosecuting, either directly or in any
other capacity, any Released and Settled Claims against any of the Released
Parties. The Released and Settled Claims are hereby compromised, settled,

                                       3
<PAGE>

released, discharged and dismissed as against the Released Parties on the merits
and with prejudice by virtue of the proceedings herein and this Order and Final
Judgment.

         6. The Defendants, the Released Parties, and the successors and assigns
of any of them, are hereby permanently barred and enjoined from instituting,
commencing or prosecuting, either directly or in any other capacity, any
Released and Settled Defendants' Claims against any of the Lead Plaintiffs, the
Jacksonville Police & Fire Pension Fund, other Class Members or their attorneys.
The Released and Settled Defendants' Claims are hereby compromised, settled,
released, discharged and dismissed on the merits and with prejudice by virtue of
the proceedings herein and this Order and Final Judgment.

         7. Neither the Stipulation, nor any of its terms and provisions, nor
any of the negotiations or proceedings connected with it, nor any of the
documents or statements referred to therein shall be:

                  a. offered or received against the Defendants as evidence of
or construed as or deemed to be evidence of any presumption, concession, or
admission by any of the Defendants of the truth of any fact alleged by
Plaintiffs or the validity of any claim that has been or could have been or
could be asserted in the Action or in any litigation, or the deficiency of any
defense that has been or could have been asserted in the Action or in any
litigation, or of any liability, negligence, fault, or wrongdoing of the
Defendants;

                  b. offered or received against the Defendants as evidence of a
presumption, concession or admission of any fault, misrepresentation or omission
with respect to any statement or written document approved or made by any
Defendant, or against the Lead Plaintiffs or the other members of the Class as
evidence of any infirmity in the claims of Lead Plaintiffs and the other members
of the Class;

                                       4
<PAGE>

                  c. offered or received against the Defendants as evidence of a
presumption, concession or admission of any liability, negligence, fault or
wrongdoing, or in any way referred to for any other reason as against any of the
parties to the Stipulation, in any other civil, criminal or administrative
action or proceeding, other than such proceedings as may be necessary to
effectuate the provisions of the Stipulation;

                  d. construed against the Defendants or the Lead Plaintiffs and
the other members of the Class as an admission or concession that the
consideration to be given hereunder represents the amount which could be or
would have been recovered after trial; and

                  e. construed as or received in evidence as an admission,
concession or presumption against Lead Plaintiffs or the other members of the
Class or any of them that any of their claims are without merit or that damages
recoverable under the Complaint would not have exceeded the Settlement Fund.

         8. The Plan of Allocation is approved as fair and reasonable, and in
the best interests of the Class, and Plaintiffs' Co-Lead Counsel and the Claims
Administrator are directed to administer the Stipulation in accordance with its
terms and provisions.

         9. Counsel for Lead Plaintiffs and the other members of the Class are
hereby awarded ___% of the Gross Settlement Fund as and for their attorneys'
fees, which sum the Court finds to be fair and reasonable, and $__________ in
reimbursement of expenses, which shall be paid to Plaintiffs' Co-Lead Counsel
from the Settlement Fund with interest from the date such Settlement Fund was
funded to the date of payment at the same rate that the Settlement Amount earns.
The award of attorneys' fees shall be allocated among Plaintiffs' Counsel in a
fashion which, in the opinion of Plaintiffs' Co-Lead Counsel, fairly compensates
Plaintiffs' Counsel for their respective contributions in the prosecution of the
Action.

                                       5
<PAGE>

         10. In setting the foregoing counsel fee, as a percentage of the common
fund recovery obtained for the Class herein, this Court has considered the
following factors set forth in CAMDEN 1 CONDOMINIUM ASSOCIATION, INC. V. DUNKLE,
946 F. 2d 768 (11th Cir. 1991); (1) the novelty and complexity of the federal
securities law issues involved; (2) the favorable result obtained for the Class;
(3) the fact that this action was prosecuted on a contingent fee basis; (4) the
experience of counsel on both sides; and (5) the fee customarily awarded for
such litigation in this District and other courts in this Circuits.

         11. The Court finds that during the course of this Action, the parties
and their respective counsel at all times complied with the requirements of
Federal Rule of Civil Procedure 11.

         12. Exclusive jurisdiction is hereby retained over the parties and the
Class Members for all matters relating to this litigation, including the
administration, interpretation, effectuation or enforcement of the Stipulation
and this Order and Final Judgment, and including any application for fees and
expenses incurred in connection with administering and distributing the
settlement proceeds to the members of the Class.

         13. An appeal of the portion of this Order which awards attorneys' fees
or expenses, shall have no effect whatsoever on the finality of any other
portion of this Order and Final Judgment or the Effective Date of the Settlement
as provided in the Stipulation. Class Members appealing this Order and Final
Judgment or any portion thereof, must first timely intervene pursuant to Federal
Rule of Civil Procedure 24.

         14. Without further order of the court, the parties may agree to
reasonable extensions of time to carry out any of the provisions of the
Stipulation.

         15. There is no just reason for delay in the entry of this Order and
Final Judgment and immediate entry by the Clerk of the Court is expressly
directed pursuant to Rule 54(b) of the Fed. R. Civ. P.

         DONE AND ORDERED, in Chambers at Miami, Miami-Dade County, Florida,
this __ day of _____________, 2002.

                                           -------------------------------------
                                           THE HONORABLE JOSE A. GONZALEZ, JR.
                                           UNITED STATES DISTRICT COURT JUDGE

Copies furnished to all counsel on the attached Service List

                                       6<PAGE>

                                                                   EXHIBIT 10.35

                             BACK YARD BURGERS, INC.

                           2002 EQUITY INCENTIVE PLAN

<PAGE>

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                                              Page
<S>                                                                                                           <C>
1.       Purpose.................................................................................................1

2.       Definitions.............................................................................................1

3.       Scope of the Plan.......................................................................................5

4.       Administration..........................................................................................5

5.       Eligibility.............................................................................................6

6.       Conditions to Grants....................................................................................7

7.       Non-transferability.....................................................................................9

8.       Exercise...............................................................................................10

9.       Loans and Guarantees...................................................................................11

10.      Notification under Section 83(b).......................................................................11

11.      Mandatory Tax Withholding..............................................................................12

12.      Elective Share Withholding.............................................................................12

13.      Termination of Employment..............................................................................12

14.      Substituted Awards.....................................................................................14

15.      Securities Law Matters.................................................................................14

16.      No Employment Rights...................................................................................14

17.      No Rights as a Stockholder.............................................................................15

18.      Nature of Payments.....................................................................................15

19.      Non-uniform Determinations.............................................................................15

20.      Adjustments............................................................................................15

21.      Amendment of the Plan..................................................................................16

22.      Termination of the Plan................................................................................16

23.      No Illegal Transactions................................................................................16

24.      Controlling Law........................................................................................16

25.      Severability...........................................................................................16
</TABLE>

<PAGE>

                             BACK YARD BURGERS, INC.
                           2002 EQUITY INCENTIVE PLAN

         The 2002 Equity Incentive Plan (the "Plan"), as established by Back
Yard Burgers, Inc., a Delaware corporation (the "Company"), is effective as of
March 28, 2002, subject to the approval of the Stockholders of the Company
within 12 months thereafter.

         1. PURPOSE. The Plan is intended to allow employees and certain others
to acquire or increase equity ownership in the Company, thereby strengthening
their commitment to the success of the Company and stimulating their efforts on
behalf of the Company, and to assist the Company in attracting new employees and
retaining existing employees.

         2. DEFINITIONS.

         The terms set forth below have the following meanings (such meanings to
be applicable to both the singular and plural forms):

                  (a) "Award" means options, including incentive stock options
         (ISOs), Restricted Shares or stock appreciation rights (SARs) granted
         under the Plan.

                  (b) "Award Agreement" means the written agreement by which an
         Award shall be evidenced.

                  (c) "Board" means the Board of Directors of the Company.

                  (d) "Cause" means any one or more of the following, as
         determined by the Committee:

                           (i) a Grantee's commission of a crime that is likely
                  to result in injury to the Company or a Subsidiary;

                           (ii) the material violation by the Grantee of written
                  policies of the Company or a Subsidiary;

                           (iii) the habitual neglect by the Grantee in the
                  performance of his or her duties to the Company or a
                  Subsidiary; or

                           (iv) the action or inaction in connection with his or
                  her duties to the Company or a Subsidiary resulting in a
                  material injury to the Company or a Subsidiary; and

                  (e) "Change in Control" shall be deemed to have occurred if:

                           (i) any "person," as defined in Sections 13(d) and
                  14(d) of the Exchange Act (other than (i) a trustee or other
                  fiduciary holding securities under an employee benefit plan of
                  the Company, or (ii) the Company or a corporation owned,
                  directly or indirectly, by the stockholders of the Company in
                  substantially

<PAGE>

                  the same proportions as their ownership of stock of the
                  Company) is or becomes the "beneficial owner" (as defined in
                  Rule 13d-3 under the Exchange Act), directly or indirectly, of
                  securities of the Company representing 50% or more of the
                  combined voting power of the Company's then outstanding
                  securities unless prior thereto, the Continuing Directors (as
                  defined below) approves the transaction that results in the
                  person becoming the beneficial owner of 50% or more of the
                  combined voting power of the Company's then outstanding
                  securities. "Continuing Directors" means directors who were
                  directors of the Company at the beginning of the 24-month
                  period ending on the date the determination is made or whose
                  election, or nomination for election, by the Company's
                  stockholders was approved by at least a majority of the
                  directors who are in office at the time of the election or
                  nomination and who either (x) were directors at the beginning
                  of the period or (y) were elected, or nominated for election,
                  by at least a majority of the directors who were in office at
                  the time of the election or nomination and were directors at
                  the beginning of the period;

                           (ii) at any time Continuing Directors no longer
                  constitute a majority of the directors of the Company;

                           (iii) the Board fixes a record date for determining
                  stockholders entitled to vote upon (x) a merger or
                  consolidation of the Company, statutory share exchange, or
                  other similar transaction with another corporation,
                  partnership, or other entity or enterprise in which either the
                  Company is not the surviving or continuing corporation or
                  Shares are to be converted into or exchanged for cash,
                  securities other than Shares, or other property, (y) a sale or
                  disposition of all or substantially all of the assets of the
                  Company, or (z) the dissolution of the Company; or

                           (iv) the Company enters into an agreement with any
                  person, entity, or enterprise the consummation of which would
                  result in the occurrence of an event described in
                  subparagraphs (i), (ii), or (iii) of this paragraph.

         Notwithstanding the foregoing, in no event shall a "Change in Control"
be deemed to have occurred with respect to a participant if the participant is
part of a purchasing group that consummates the Change in Control transaction. A
participant shall be deemed "part of a purchasing group" for purposes of the
immediately preceding sentence if the participant is an equity participant in
the purchasing company or group other than as a result of (y) passive ownership
of less than five percent of the voting capital stock or voting equity interests
of the purchasing company; or (z) equity participation in the purchasing company
or group that is otherwise not significant, as determined prior to the Change in
Control by a majority of the Continuing Directors.

                  (f) "Code" means the Internal Revenue Code of 1986, as amended
         or superceded, and regulations and rulings thereunder. References to a
         particular section of the Code include references to successor
         provisions.

                                       2

<PAGE>

                  (g) "Committee" means the committee of the Board appointed
         pursuant to Section 4(a).

                  (h) "Common Stock" means the common stock, $.01 par value per
         share, of the Company.

                  (i) "Disability" means the inability of the Grantee to
         reasonably perform his or her employment responsibilities, in the
         opinion of a licensed physician for the Company, due to physical or
         mental impairments for a period of sixty (60) consecutive days.

                  (j) "Effective Date" means the earlier of the date the Plan is
         adopted or the date the Plan is approved by the stockholders of the
         Company.

                  (k) "Eligible Employee" means any employee (including any
         officer) of the Company or any Subsidiary, including any employee on an
         approved leave of absence or layoff, if such leave or layoff does not
         qualify as a Disability.

                  (l) "Fair Market Value" of an equity security as of any date
         means:

                           (i) the closing price of a share of such equity
                  security on the Nasdaq Small Cap Market (or such other
                  exchange on which such security is principally traded) on the
                  relevant date or, if there were no sales on that date, the
                  closing price on the next preceding date on which there were
                  sales.

                           (ii) if the Shares of the Company are not listed and
                  traded on a national securities exchange as of the date in
                  question, the fair market value shall be the mean between the
                  lowest reported bid price and highest reported asked price of
                  the Shares on the date in question in the over-the-counter
                  market, as such prices are reported in publication of general
                  circulation selected by the Company and regularly reporting
                  the market price of the Shares in such market.

                           (iii) if the Shares of the Company are not listed or
                  admitted to trading on any stock exchange or traded in the
                  over-the-counter market as of the date in question, the fair
                  market value shall be determined in good faith by the
                  Committee.

                  (m) "Grantee" means an individual who has been granted an
         Award.

                  (n) "Immediate Family" means, with respect to a particular
         Grantee, such Grantee's spouse, children and grandchildren.

                  (o) "Mature Shares" means Shares for which the holder thereof
         has good title, free and clear of all liens and encumbrances, and which
         such holder either (i) has held for at least six months or (ii) has
         purchased on the open market.

                                       3

<PAGE>

                  (p) "1934 Act" means the Securities Exchange Act of 1934, as
         amended. References to a particular section of, or rule under, the 1934
         Act include references to successor provisions.

                  (q) "Option Price" means the per share exercise price of an
         option.

                  (r) "Option Term" means the period beginning on the Grant Date
         of an option and ending on the expiration date of such option, as
         specified in the Award Agreement for such option and as may, in the
         discretion of the Committee and consistent with the provisions of the
         Plan, be extended from time to time prior to the expiration date of
         such stock option then in effect.

                  (s) "Restricted Shares" means Shares that are subject to
         forfeiture if the Grantee does not satisfy the conditions specified in
         the Award Agreement applicable to such Shares.

                  (t) "Retirement" means a termination of employment by a
         Grantee upon attaining either (i) age 55 with at least 20 years of
         service as an employee of the Company or a Subsidiary or (ii) age 60
         with at least 15 years of service as an employee of the Company or a
         Subsidiary.

                  (u) "Rule 16b-3" means Rule 16b-3 of the SEC under the 1934
         Act, as amended from time to time, together with any successor rule.

                  (v) "SAR" means stock appreciation right.

                  (w) "SEC" means the Securities and Exchange Commission.

                  (x) "Section 16 Person" means a person who is subject to
         potential liability under Section 16(b) of the 1934 Act with respect to
         transactions involving equity securities of the Company.

                  (y) "Share" means a share of Common Stock.

                  (z) "Subsidiary" means, for purposes of grants of incentive
         stock options, a corporation as defined in Section 424(f) of the Code
         (with the Company being treated as the employer corporation for
         purposes of this definition) and, for all other purposes, a United
         States or foreign corporation with respect to which the Company owns,
         directly or indirectly, more than 50% or more of the then-outstanding
         common stock.

                  (aa) "10% Owner" means a person who owns capital stock
         (including stock treated as owned under Section 424(d) of the Code)
         possessing more than 10% of the total combined voting power of all
         classes of capital stock of the Company or any Subsidiary.

                  (bb) "Voting Power" means the combined voting power of the
         then-outstanding securities of a corporation entitled to vote generally
         in the election of directors.

                                       4

<PAGE>

         3. SCOPE OF THE PLAN. Subject to the adjustment as provided in Section
20, the total number of Shares available for grant under the Plan shall be
225,000 Shares; except that the number of Shares for which Awards may be granted
to any Grantee in any calendar year shall not exceed 35,000.

         If any Shares subject to any Award granted hereunder are forfeited or
such Award otherwise terminates without the issuance of such Shares or of other
consideration in lieu of such Shares, the Shares subject to such Award, to the
extent of any such forfeiture or termination, shall again be available for grant
under the Plan. If any outstanding ISOs under the Plan for any reason expire or
are terminated, the Shares allocable to the unexercised portion of all of such
ISOs may again be subject to an incentive stock option under the Plan. Shares
awarded under the Plan may be treasury shares or newly-issued shares.

         4. ADMINISTRATION.

                  (a) Subject to Section (b), the Plan shall be administered by
         a committee (the "Committee") which shall consist of two or more
         directors of the Company. A majority of the members of the Committee
         shall constitute a quorum, and the act of a majority of the members of
         the Committee shall be the act of the Committee. Any member of the
         Committee may be removed at any time either with or without cause by
         resolution adopted by the Board of Directors of the Company, and any
         vacancy on the Committee may at any time be filled by a resolution
         adopted by the Board of Directors. Whether or not a Committee is
         separately designated by the Board of Directors, any and all powers and
         functions of the Committee may at any time and from time to time be
         exercised by the Board of Directors. No member or former member of the
         Committee or of the Board of Directors shall be liable for any action
         or determination made in good faith with respect to the Plan or any
         option granted hereunder. The number of members of the Committee shall
         from time to time be increased or decreased.

                  (b) Subject to the express provisions of the Plan, the
         Committee has full and final authority and sole discretion as follows:

                           (i) to determine when and to whom Awards should be
                  granted and the terms and conditions applicable to each Award,
                  including the benefit payable under any SAR, and whether or
                  not specific Awards shall be identified with other specific
                  Awards, and if so whether they shall be exercisable
                  cumulatively with, or alternatively to, such other specific
                  Awards;

                           (ii) to determine the amount, if any, that a Grantee
                  shall pay for Restricted Shares, whether to permit or require
                  the payment of cash dividends thereon to be deferred and the
                  terms related thereto, when Restricted Shares (including
                  Restricted Shares acquired upon the exercise of an option)
                  shall be forfeited and whether such shares shall be held in
                  escrow;

                           (iii) to interpret the Plan and to make all
                  determinations necessary or advisable for the administration
                  of the Plan;

                                       5

<PAGE>

                           (iv) to make, amend and rescind rules relating to the
                  Plan, including rules with respect to the exercisability and
                  nonforfeitability of Awards upon the termination of employment
                  of a Grantee;

                           (v) to determine the terms and conditions of all
                  Award Agreements (which need not be identical) and, with the
                  consent of the Grantee, to amend any such Award Agreement at
                  any time, among other things, to permit transfers of such
                  Awards to the extent permitted by the Plan, except that the
                  consent of the Grantee shall not be required for any amendment
                  which (A) does not adversely affect the rights of the Grantee,
                  or (B) is necessary or advisable (as determined by the
                  Committee) to carry out the purpose of the Award as a result
                  of any new or change in existing applicable law;

                           (vi) to cancel, with the consent of the Grantee,
                  outstanding Awards and to grant new Awards in substitution
                  therefor;

                           (vii) to accelerate the exercisability (including
                  exercisability within a period of less than one year after the
                  Grant Date) of, and to accelerate or waive any or all of the
                  terms and conditions applicable to, any Award or any group of
                  Awards for any reason and at any time, including in connection
                  with a termination of employment (other than for Cause);

                           (viii) subject to Section 6(c), to extend the time
                  during which any Award or group of Awards may be exercised;

                           (ix) to impose such additional terms and conditions
                  upon the grant, exercise or retention of Awards as the
                  Committee may, before or concurrently with the grant thereof,
                  deem appropriate, including limiting the percentage of Awards
                  which may from time to time be exercised by a Grantee; and

                           (x) to take any other action with respect to any
                  matters relating to the Plan for which it is responsible.

         The determination of the Committee on all matters relating to the Plan
or any Award Agreement shall be final. No member of the Committee shall be
liable for any action or determination made in good faith with respect to the
Plan or any Award.

         5. ELIGIBILITY. The Committee may in its discretion grant Awards to any
Eligible Employee, whether or not he or she has previously received an Award. In
addition, the Committee in its discretion may grant nonqualified options (but
not ISOs), Restricted Stock or SARs to non-employee directors, independent
contractors or consultants of the Company or its Subsidiaries who render those
types of services which tend to contribute to the success of the Company or its
Subsidiaries, or which may reasonably be anticipated to contribute to the future
success of the Company or its Subsidiaries.

                                       6

<PAGE>

         6. CONDITIONS TO GRANTS.

                  (a) General Conditions.

                           (i) The Grant Date of an Award shall be the date on
                  which the Committee grants the Award or such later date as
                  specified in advance by the Committee.

                           (ii) Any provision of the Plan to the contrary
                  notwithstanding, the Option Term shall under no circumstances
                  extend more than 10 years after the Grant Date, and shall be
                  subject to earlier termination as herein provided.

                           (iii) To the extent not set forth in the Plan, the
                  terms and conditions of each Award shall be set forth in an
                  Award Agreement.

                  (b) Grant of Options.

                           (i) No later than the Grant Date of any option, the
                  Committee shall determine the Option Price of such option.
                  Only nonqualified options may be granted with an Option Price
                  that is less than the Fair Market Value of a Share on the
                  Grant Date. An option shall be exercisable for unrestricted
                  Shares unless the Award Agreement provides that it is
                  exercisable for Restricted Shares.

                           (ii) The Committee may, in its discretion, permit an
                  employee to elect, before earning compensation, to be granted
                  an Award in lieu of receiving such compensation; if in the
                  judgment of the Committee, the value of such Award on the
                  Grant Date equals the amount of compensation foregone by such
                  employee.

                  (c) Grant of Incentive Stock Options. At the time of the grant
         of any option, the Committee may, in its discretion, designate that
         such option shall be made subject to additional restrictions to permit
         it to qualify as an "incentive stock option" under the requirements of
         Section 422 of the Code. Any option designated as an ISO:

                           (i) shall have an Option Price not less than 100% of
                  the Fair Market Value of a Share on the Grant Date;

                           (ii) shall, if granted to a 10% Owner, have an Option
                  Price not less than 110% of the Fair Market Value of a Share
                  on the Grant Date;

                           (iii) shall be for a period of not more than 10 years
                  (five years in the case of an ISO granted to a 10% Owner) from
                  the Grant Date, and shall be subject to earlier termination as
                  provided herein or in the applicable Award Agreement;

                           (iv) shall meet the limitations of this subparagraph
                  6(c)(iv). If the aggregate Fair Market Value of Shares with
                  respect to which ISOs first become exercisable by a Grantee in
                  any calendar year exceeds $100,000, taking into account Shares
                  subject to all ISOs granted by the Company which are held by
                  the Grantee, the excess will be treated as nonqualified
                  options. To determine whether

                                       7

<PAGE>

                  the $100,000 limit is exceeded, the Fair Market Value of
                  Shares subject to options shall be determined as of the Award
                  dates of the options. In reducing the number of options
                  treated as ISOs to meet the $100,000 limit, the most recently
                  granted Options will be reduced first. If a reduction of
                  simultaneously granted options is necessary to meet the
                  $100,000 limit, the Company may designate which Shares are to
                  be treated as Shares acquired pursuant to an ISO.

                           (v) shall be granted within 10 years from the earlier
                  of the date the Plan is adopted or the date the Plan is
                  approved by the stockholders of the Company;

                           (vi) shall require the Grantee to notify the
                  Committee of any disposition of any Shares issued pursuant to
                  the exercise of the ISO under the circumstances as described
                  in Section 421(b) of the Code (relating to certain
                  disqualifying dispositions) (any such circumstance, a
                  "Disqualifying Disposition"), within 10 business days after
                  such Disqualifying Disposition; and

                           (vii) shall by its terms not be assignable or
                  transferable other than by will or the laws of descent and
                  distribution and may be exercised, during the Grantee's
                  lifetime, only by the Grantee, except that the Grantee may, to
                  the extent provided in the Plan or in any manner specified by
                  the Committee, designate in writing a beneficiary to exercise
                  his or her ISO after the Grantee's death;

         Notwithstanding any provision herein to the contrary, the Committee
may, without the consent of the Grantee, at any time before the exercise of an
option (whether or not an ISO), take any action necessary to prevent such option
from being treated as an ISO.

                  (d) Grant of SARs.

                           (i) When granted, SARs may, but need not be
                  identified with a specific option or specific Restricted
                  Shares of the Grantee (including any option or Restricted
                  Shares granted on or before the Grant Date of the SARs) in a
                  number equal to or different from the number of SARs so
                  granted. If SARs are identified with Shares subject to an
                  option or with Restricted Shares, then, unless otherwise
                  provided in the applicable Award Agreement, the Grantee's
                  associated SARs shall terminate upon (x) the expiration,
                  termination, forfeiture or cancellation of such option or
                  Restricted Shares (y) the exercise of such option or (z) the
                  date such Restricted Shares become nonforfeitable.

                           (ii) The strike price ("Strike Price") of any SAR
                  shall equal, for any SAR that is identified with an option,
                  the Option Price of such option, or for any other SAR, 100% of
                  the Fair Market Value of a Share on the Grant Date of such
                  SAR; except that the Committee may (x) specify a higher Strike
                  Price in the Award Agreement, or (y) provide that the benefit
                  payable upon exercise of any SAR shall not exceed such
                  percentage of the Fair Market Value of a Share on such Grant
                  Date as the Committee shall specify.

                  (e) Grant of Restricted Shares.

                                       8

<PAGE>

                           (i) The Committee shall determine the amount, if any,
                  that a Grantee shall pay for Restricted Shares, subject to the
                  following sentence. Such payment shall be made in full by the
                  Grantee before the delivery of the shares and in any event no
                  later than 10 business days after the Grant Date for such
                  shares. In the discretion of the Committee and to the extent
                  permitted by law, payment may also be made in accordance with
                  Section 9.

                           (ii) The Committee may, but need not, provide that
                  all or any portion of a Grantee's Restricted Shares, or
                  Restricted Shares acquired upon exercise of an option, shall
                  be forfeited:

                                    (A) except as otherwise specified in the
                           Plan or the Award Agreement, upon the Grantee's
                           termination of employment within a specified time
                           period after the Grant Date; or

                                    (B) if the Company or the Grantee does not
                           achieve specified performance goals (if any) within a
                           specified time period after the Grant Date and before
                           the Grantee's termination of employment; or

                                    (C) upon failure to satisfy such other
                           restrictions as the Committee may specify in the
                           Award Agreement.

                           (iii) If restricted Shares are forfeited, then if the
                  Grantee was required to pay for such shares or acquired such
                  Restricted Shares upon the exercise of an option, the Grantee
                  shall be deemed to have resold such Restricted Shares to the
                  Company at a price equal to the lesser of (x) the amount paid
                  by the Grantee for such Restricted Shares, or (y) the Fair
                  Market Value of a Share on the date of such forfeiture. The
                  Company shall pay to the Grantee the required amount as soon
                  as is administratively practical. Such Restricted Shares shall
                  cease to be outstanding, and shall no longer confer on the
                  Grantee thereof any rights as a Stockholder of the Company,
                  from and after the date the event causing the forfeiture,
                  whether or not the Grantee accepts the Company's tender of
                  payment for such Restricted Shares.

                           (iv) The Committee may provide that the certificates
                  for any Restricted Shares (x) shall be held (together with a
                  stock power executed in blank by the Grantee) in escrow by the
                  Secretary of the Company until such Restricted Shares become
                  nonforfeitable or are forfeited or (y) shall bear an
                  appropriate legend restricting the transfer of such Restricted
                  Shares. If any Restricted Shares become nonforfeitable, the
                  Company shall cause certificates for such shares to be issued
                  without such legend.

         7. NON-TRANSFERABILITY. An Award granted hereunder shall not be
assignable or transferable other than by will or the laws of descent and
distribution and may be exercised, during the Grantee's lifetime, only by the
Grantee or his or her guardian or legal representative, except that, subject to
Section 6(c) (in respect of ISOs), a Grantee may, if permitted by the Committee,
in its discretion, (i) designate in writing a beneficiary to exercise an Award
after his

                                       9

<PAGE>

or her death (provided, however, that no such designation shall be effective
unless received by the office of the Company designated for that purpose prior
to the Grantee's death) and (ii) transfer the Award to a member of his or her
Immediate Family.

         8. EXERCISE.

                  (a) Exercise of Options.

                           (i) Subject to Section 6 and except as otherwise
                  provided in the applicable Award Agreement, each option shall
                  become exercisable at such time or times as may be specified
                  by the Committee from time to time.

                           (ii) An option shall be exercised by the delivery to
                  the Company during the Option Term of (x) written notice of
                  intent to purchase a specific number of Shares subject to the
                  option and (y) payment in full of the Option Price of such
                  specific number of Shares.

                           (iii) Payment of the Option Price may be made by any
                  one or more of the following means:

                                    (A) cash, personal check or wire transfer;

                                    (B) Mature Shares, valued at their Fair
                           Market Value on the date of exercise;

                                    (C) with the approval of the Committee,
                           Restricted Shares held by the Grantee for at least
                           six months prior to the exercise of the option, each
                           such share valued at the Fair Market Value of a Share
                           on the date of exercise;

                                    (D) in accordance with procedures previously
                           approved by the Secretary of the Company, through the
                           sale of the Shares acquired on exercise of the Option
                           through a bank or broker-dealer to whom the Grantee
                           has submitted an irrevocable notice of exercise and
                           irrevocable instructions to deliver promptly to the
                           Company the amount of sale or loan proceeds
                           sufficient to pay for such Shares, together with, if
                           requested by the Company, the amount of federal,
                           state, local or foreign withholding taxes payable by
                           Grantee by reason of such exercise; or

                                    (E) in the discretion of the Committee,
                           payment may also be made in accordance with Section
                           9.

         The Committee may in its discretion specify that, if any Restricted
Shares ("Tendered Restricted Shares") are used to pay the Option Price, (x) all
the Shares acquired on exercise of the option shall be subject to the same
restrictions as the Tendered Restricted Shares, determined as of the date of
exercise of the option, or (y) a number of Shares acquired on exercise of the
option equal to the number of Tendered Restricted Shares shall be subject to the
same restrictions as the Tendered Restricted Shares, determined as of the date
of exercise of the option.

                                       10

<PAGE>

                  (b) Exercise of SARs.

                           (i) Subject to Section 6(d), and except as otherwise
                  provided in the applicable Award Agreement, (x) each SAR not
                  identified with any other Award shall become exercisable with
                  respect to 25% of the Shares subject thereto on each of the
                  first four anniversaries of the Grant Date of such SAR unless
                  the Committee provides otherwise in the Award Agreement and
                  (y) each SAR which is identified with any other Award shall
                  become exercisable as and to extend that the option or
                  Restricted Shares with which such SAR is identified may be
                  exercised or becomes nonforfeitable, as the case may be.

                           (ii) SARs shall be exercised by delivery to the
                  Company of written notice of intent to exercise a specific
                  number of SARs. Unless otherwise provided in the applicable
                  Award Agreement, the exercise of SARs which are identified
                  with Shares subject to an option or Restricted Shares shall
                  result in the cancellation or forfeiture of such option or
                  Restricted Shares, as the case may be, to the extent of such
                  exercise.

                           (iii) The benefit for each SAR exercised shall be
                  equal to (x) the Fair Market Value of a Share on the date of
                  such exercise, minus (y) the Strike Price of such SAR. Such
                  benefit shall be payable in cash, except that the Committee
                  may provide in the Award Agreement that benefits may be paid
                  wholly or partly in Shares.

         9. LOANS AND GUARANTEES. The Committee may in its discretion allow a
Grantee to defer payment to the Company of all or any portion of (i) the Option
Price of an option, (ii) the purchase price of Restricted Shares, or (iii) any
taxes associated with the exercise, nonforfeitability of, or payment of benefits
in connection with, an Award, or cause the Company to guarantee a loan from a
third party to the Grantee, in an amount equal to all or any portion of such
Option Price, or any related taxes. Any such payment deferral or guarantee by
the Company shall be on such terms and conditions as the Committee may determine
except that a Grantee shall not be entitled to defer the payment of such Option
Price, purchase price or any related taxes unless the Grantee enters into a
binding, recourse obligation to pay the deferred amount, which recourse
obligation shall include a fixed, market rate of interest that is non-prepayable
and nonrefundable. If the Committee has permitted a payment deferral or caused
the Company to guarantee a loan in accordance with this Section, then the
Committee may require the immediate payment of such deferred amount or the
immediate release of such guarantee upon the Grantee's termination of employment
or if the Grantee sells or otherwise transfers his or her Shares purchased
pursuant to such deferral or guarantee.

         10. NOTIFICATION UNDER SECTION 83(B). If the Grantee, in connection
with the exercise of any option, or the grant of Restricted Shares, makes the
election permitted under Section 83(b) of the Code to include in such Grantee's
gross income in the year of transfer the amounts

                                       11

<PAGE>

specified in Section 83(b) of the Code, then such Grantee shall notify the
Company of such election within 10 days of filing the notice of the election
with the Internal Revenue Service, in addition to any filing and notification
required pursuant to regulations issued under Section 83(b) of the Code. The
Committee may, in connection with the grant of an Award or at any time
thereafter, prohibit a Grantee from making the election described above.

         11. MANDATORY TAX WITHHOLDING.

                  (a) Whenever Shares are to be delivered under the Plan upon
         exercise or payment of an Award or upon Restricted Shares becoming
         nonforfeitable, or any other event with respect to rights and benefits
         hereunder, the Company shall be entitled to require (i) that the
         Grantee remit an amount in cash, or in the Company's discretion, Mature
         Shares, sufficient to satisfy all federal, state, and local tax
         withholding requirements related thereto ("Required Withholding"), (ii)
         the withholding of such Required Withholding from compensation
         otherwise due to the Grantee or from any Shares due to the Grantee
         under the Plan or (iii) any combination of the foregoing.

                  (b) Any Grantee who makes a Disqualifying Disposition or an
         election under Section 83(b) of the Code shall remit to the Company an
         amount sufficient to satisfy all resulting Required Withholding; except
         that in lieu of or in addition to the foregoing, the Company shall have
         the right to withhold such Required Withholding from compensation
         otherwise due to the Grantee or from any Shares or other payment due to
         the Grantee under the Plan.

         12. ELECTIVE SHARE WITHHOLDING.

                  (a) Subject to the following subsection, and unless otherwise
         provided in the Award Agreement, a Grantee may elect the withholding
         ("Share Withholding") by the Company of a portion of the Shares
         otherwise deliverable to such Grantee upon the exercise of an Award or
         upon Restricted Shares becoming nonforfeitable (each, a "Taxable
         Event") having a Fair Market Value equal to the minimum amount
         necessary to satisfy Required Withholding liability attributable to the
         Taxable Event.

                  (b) Each Share Withholding election shall be subject to the
         following conditions:

                           (i) any Grantee's election shall be subject to the
                  Committee's discretion to revoke the Grantee's right to elect
                  Share Withholding at any time before the Grantee's election if
                  the Committee has reserved the right to do so in the Award
                  Agreement;

                           (ii) the Grantee's election must be made before the
                  date (the "Tax Date") on which the amount to be withheld is
                  determined; and

                           (iii) the Grantee's election shall be irrevocable.

                                       12

<PAGE>

         13. TERMINATION OF EMPLOYMENT.

                  (a) For Cause. If a Grantee's employment is terminated for
         Cause, (i) the Grantee's Restricted Shares that are forfeitable shall
         thereupon be forfeited, subject to the provisions of Section 6(e)(iii)
         regarding repayment of certain amounts to the Grantee; and (ii) any
         unexercised option or performance share shall terminate effective
         immediately upon such termination of employment.

                  (b) On Account of Retirement. Except as otherwise provided by
         the Committee in the Award Agreement, if a Grantee's employment
         terminates on account of Retirement, then:

                           (i) the Grantee's Restricted Shares that were
                  forfeitable shall thereupon become nonforfeitable; and

                           (ii) any unexercised option or SAR, whether or not
                  exercisable on the date of such termination of employment, may
                  be exercised, in whole or in part, within the first two (2)
                  years after such termination of employment (but only during
                  the Option Term) by the Grantee.

                  (c) On Account of Death. Except as otherwise provided by the
         Committee in the Award Agreement, if a Grantee's employment terminates
         on account of death, then:

                           (i) the Grantee's Restricted Shares that were
                  forfeitable shall thereupon become nonforfeitable; and

                           (ii) any unexercised option or SAR, whether or not
                  exercisable on the date of such termination of employment, may
                  be exercised, in whole or in part, within the first 12 months
                  after such termination of employment (but only during the
                  Option Term) by the Grantee or, after his or her death, by (A)
                  his or her personal representative or by the person to whom
                  the option or SAR, as applicable, is transferred by will or
                  the applicable laws of descent and distribution, or (B) the
                  Grantee's designated beneficiary.

                  (d) On Account of Disability. Except as otherwise provided by
         the Committee in the Award Agreement, if a Grantee's employment
         terminates on account of Disability, then:

                           (i) the Grantee's Restricted Shares that were
                  forfeitable shall thereupon become nonforfeitable; and

                           (ii) any unexercised option or SAR, whether or not
                  exercisable on the date of such termination of employment, may
                  be exercised in whole or in part, within the first 12 months
                  after such termination of employment (but only during the
                  Option Term) by the Grantee or, after his or her death, by (A)
                  his or her personal representative or by the person to whom
                  the option or SAR, as applicable, is transferred by will or
                  the applicable laws of descent and distribution, or (B) the
                  Grantee's designated beneficiary.

                                       13

<PAGE>

                  (e) Any Other Reason. Except as otherwise provided by the
         Committee in the Award Agreement, if a Grantee's employment terminates
         for any reason other than for Cause, Retirement, death, or Disability,
         then:

                           (i) the Grantee's Restricted Shares (and any SARs
                  identified therewith), to the extent forfeitable on the date
                  of the Grantee's termination of employment, shall be forfeited
                  on such date; and

                           (ii) any unexercised option or SAR (other than a SAR
                  identified with a Restricted Share), to the extent exercisable
                  immediately before the Grantee's termination of employment,
                  may be exercised in whole or in part, not later than three
                  months after such termination of employment (but only during
                  the Option Term).

                  (f) Extension of Term. In the event of a termination of the
         Grantee's employment other than for Cause, the term or any Award
         (whether or not exercisable immediately before such termination) which
         would otherwise expire after the Grantee's termination of employment
         but before the end of the period following such termination of
         employment described in subparagraphs (b), (c) and (d) of this Section
         for exercise of Awards may, in the Committee's discretion, be extended
         so as to permit any unexercised portion thereof to be exercised at any
         time within such period. The Committee may further extend the period of
         exercisability to permit any unexercised portion thereof to be
         exercised within a specified period provided by the Committee.

         14. SUBSTITUTED AWARDS. If the Committee cancels any Award (whether
granted under this Plan or any plan of any entity acquired by the Company or a
Subsidiary), the Committee may, in its discretion, substitute a new Award
therefor upon such terms and conditions consistent with the Plan as the
Committee may determine; except that (a) the Option Price of any new option, and
the Strike Price of any new SAR, shall not be less than 100% (110% in the case
of an incentive stock option granted to a 10% Owner) of the Fair Market Value of
a Share on the date of grant of the new Award; and (b) the Grant Date of the new
Award shall be the date on which such new Award is granted.

         15. SECURITIES LAW MATTERS. If the Committee deems necessary to comply
with any applicable securities law, the Committee may require a written
investment intent representation by the Grantee and may require that a
restrictive legend be affixed to certificate for Shares. If, based upon the
advice of counsel to the Company, the Committee determines that the exercise or
nonforfeitability of, or delivery of benefits pursuant to, any Award would
violate any applicable provision of (i) federal or state securities laws or (ii)
the listing requirements of any national securities exchange or national market
system on which are listed any of the Company's equity securities, then the
Committee may postpone any such exercise, nonforfeitability or delivery, as
applicable, but the Company shall use all reasonable efforts to cause such
exercise, nonforfeitability or delivery to comply with all such provisions at
the earliest practicable date.

         16. NO EMPLOYMENT RIGHTS. Neither the establishment of the Plan, nor
the grant of any Award shall (a) give any Grantee the right to remain employed
by the Company or any

                                       14

<PAGE>

Subsidiary or to any benefits not specifically provided by the Plan or (b)
modify the right of the Company or any Subsidiary to modify, amend, or terminate
any employee benefit plan.

         17. NO RIGHTS AS A STOCKHOLDER. A Grantee shall not have any rights as
a stockholder of the Company with respect to the Shares (other than Restricted
Shares) which may be deliverable upon exercise or payment of such Award until
such shares have been delivered to him or her. Restricted Shares, whether held
by a Grantee or in escrow by the Secretary of the Company, shall confer on the
Grantee all rights of a stockholder of the Company, except as otherwise provided
in the Plan. At the time of a grant of Restricted Shares, the Committee may
require the payment of cash dividends thereon to be deferred and, if the
Committee so determines, reinvested in additional Restricted Shares. Stock
dividends and deferred cash dividends issued with respect to Restricted Shares
shall be subject to the same restrictions and other terms as apply to the
Restricted Shares with respect to which such dividends are issued. The Committee
may in its discretion provide for payment of interest on deferred cash
dividends.

         18. NATURE OF PAYMENTS. Awards shall be special incentive payments to
the Grantee and shall not be taken into account in computing the amount of
salary or compensation of the Grantee for purposes of determining any pension,
retirement, death or other benefit under (a) any pension, retirement,
profit-sharing, bonus, insurance or other employee benefit plan of the Company
or any Subsidiary or (b) any agreement between (i) the Company or any Subsidiary
and (ii) the Grantee, except as such plan or agreement shall otherwise expressly
provide.

         19. NON-UNIFORM DETERMINATIONS. The Committee's determinations under
the Plan need not be uniform and may be made by the Committee selectively among
persons who receive, or are eligible to receive, Awards, whether or not such
persons are similarly situated. Without limiting the generality of the
foregoing, the Committee shall be entitled, to enter into non-uniform and
selective Award Agreements as to (a) the identity of the Grantees, (b) the terms
and provisions of Awards, and (c) the treatment of terminations of employment

         20. ADJUSTMENTS.

                  (a) The Committee shall make equitable adjustment of:

                           (i) the aggregate numbers and kind of Shares
                  available under the Plan for Awards in general and for the
                  grant of ISOs;

                           (ii) the number and kind of Shares and SARs covered
                  by an Award, and

                           (iii) the Option Price of all outstanding options and
                  the Strike Price of all outstanding SARs,

to reflect a stock dividend, stock split, reverse stock split, share
combination, recapitalization, merger, consolidation, spin-off, split-off,
reorganization, rights offering, liquidation or similar event, of or by the
Company.

                  (b) Notwithstanding any provision in this Plan or any Award
         Agreement, in the event of a Change in Control in connection with which
         the holders of Common Stock

                                       15

<PAGE>

         receive shares of common stock of the surviving or successor
         corporation that are registered under Section 12 of the 1934 Act:

                           (i) there shall be substituted for each option and
                  SAR outstanding on the date of the consummation of corporate
                  transaction relating to such Change in Control, a new option
                  or SAR, as the case may be, reflecting the number and class of
                  shares into which each outstanding Share shall be converted
                  pursuant to such Change in Control and providing each Grantee
                  with rights that are substantially identical to those under
                  this Plan in all material respects; and

                           (ii) in the event of any such substitution, the
                  purchase price per share in the case of an option and the
                  Strike Price in the case of an SAR shall be appropriately
                  adjusted by the Committee, such adjustments to be made in the
                  case of outstanding options and SARs without a change in the
                  aggregate purchase price or Strike Price.

         21. AMENDMENT OF THE PLAN. The Board may from time to time, in its
discretion, amend the Plan without the approval of the Company's Stockholders,
except (i) as such stockholder approval may be required under the listing
requirements of any securities exchange or national market system on which are
listed the Company's equity securities and (ii) that the Board may not without
the approval of the Company's Stockholders amend the Plan to (x) increase the
total number of shares reserved for the purposes of the Plan or (y) change the
employees, class of employees or others persons eligible to participate in the
Plan.

         22. TERMINATION OF THE PLAN. The Plan shall terminate on the ten-year
anniversary of the Effective Date or at such earlier time as the Board may
determine. No termination shall affect any Award then outstanding under the
Plan.

         23. NO ILLEGAL TRANSACTIONS. The Plan and all Awards granted pursuant
to it are subject to all applicable laws and regulations. Notwithstanding any
provision of the Plan or any Award, Grantees shall not be entitled to exercise,
or receive benefits under, any Award, and the Company shall not be obligated to
deliver any Shares or deliver benefits to a Grantee, if such exercise or
delivery would constitute a violation by the Grantee or the Company of any
applicable law or regulation.

         24. CONTROLLING LAW. The law of the State of Tennessee, except its law
with respect to choice of law, shall control all matters relating to the Plan.

         25. SEVERABILITY. If any part of the Plan is declared by any court of
governmental authority to be unlawful or invalid, such unlawfulness or
invalidity shall not invalidate any other part of the Plan. Any Section or part
of a Section so declared to be unlawful or invalid shall, if possible, be
construed in a manner which will given effect to the terms of such Section to
the fullest extent possible while remaining lawful and valid.

                                       16

<PAGE>

                                   CERTIFICATE

         I, William N. Griffith, Secretary of Back Yard Burgers, Inc., certify
that the foregoing is a true and correct copy of the Back Yard Burgers, Inc.
2002 Equity Incentive Plan as adopted by the Board of Directors of the
corporation on March 28, 2002.

                                       By /s/ William N. Griffith
                                          --------------------------------------

                                       Name  William N. Griffith
                                            ------------------------------------
                                              Secretary

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}]]